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ABSTRACT 
 
 
 Oncogenic signaling by the Philadelphia chromosome-encoded BCR-ABL fusion 
kinase initiates and drives both Philadelphia chromosome-positive acute lymphoblastic 
leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Food and Drug 
Administration (FDA)-approved BCR-ABL-specific kinase inhibitors (BCR-ABL–KIs) 
imatinib, dasatinib and nilotinib induce prolonged remissions in CML but poor leukemia-
reduction and relapse-control in Ph+ ALL. The relative primary BCR-ABL–KI-resistance 
in Ph+ ALL patients carrying predominantly BCR-ABLWT disease cannot be attributed to 
drug-resistant BCR-ABL mutations (BCR-ABLMUTANTS), and remains poorly understood. 
 
We established a cell-based platform to evaluate the modulation of anti-Ph+ ALL 
activity of drugs by both tumor-extrinsic cytokines normally present in the leukemia 
microenvironment and tumor-intrinsic vector-mediated alteration of candidate genes. We 
identified that BCR-ABLWT-driven Ph+ ALL cells are rendered significantly resistant 
against all FDA-approved BCR-ABL–KIs by 1) Several host-cytokines, but most 
dominantly by Interleukin7 (IL7), and 2) Cell-intrinsic functional-loss of IKAROS. 
Utilizing IL7-deficient recipient mice, we demonstrated that physiological levels of IL7 
significantly attenuate the survival benefit derived from dasatinib monotherapy against 
Ph+ ALL. Follow-up mechanistic studies using cell signaling and gene expression 
comparisons indicated that IL7 imparts chemo-refractoriness by initiating IL7-pSTAT5-
c-MYC signaling. Interestingly, IKAROS haploinsufficiency, which has been previously 
associated with poor clinical prognosis in patients with Ph+ ALL, was recently 
demonstrated to directly de-repress c-MYC expression. This suggested that both cell-
extrinsic IL7 and cell-intrinsic IKAROS loss converge on c-MYC, which may act as node 
of leukemia BCR-ABL–KI-refractoriness. We confirmed that vector-mediated 
modifications imitating IL7 induction of STAT5 activity, functional-loss of IKAROS, and 
c-MYC over-expression, all selectively enrich Ph+ ALL cells during prolonged 
exposures to imatinib and dasatinib, thus revealing new chemo-refractory phenotypes. 
 
Contemporary medicine advocates co-treatment with agents of complementary 
mechanism of drug-action to tackle drug resistance. To identify combination agents that 
could overcome the dasatinib-resistant phenotypes of Ph+ ALL, we screened a library of 
3200 agents including known anti-infective and chemotherapy drugs. We discovered that 
a well known anti-malarial drug dihydroartemisinin (DHA) killed host-IL7-protected 
BCR-ABLWT, c-MYC-overexpressing BCR-ABLWT and BCR-ABLMUTANT Ph+ ALL 
cells in vitro. In vivo, DHA displayed weak activity as a single agent but its addition 
synergistically augmented the leukemia reduction by dasatinib, relative to either of the 
two drugs alone. Remarkably, DHA and dasatinib combination regimen eliminated 
host-protected dasatinib-refractory persistent leukemia and improved long-term survival 
from 0 to >90% in a murine model that faithfully captures the BCR-ABL–KI 
drug-refractoriness of human Ph+ ALL. 
 
This study: 1) Uncovers novel mechanisms of clinical drug-resistance against 
BCR-ABL–KIs, 2) Identifies increased levels of IL7, pSTAT5 and c-MYC protein, and 
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IKAROS haploinsufficiency as potential biomarkers of BCR-ABL-targeted 
drug-resistance, 3) Strongly supports clinical exploration of the BCR-ABL–KI and DHA 
combinations for treating patients with Ph+ ALL, and 4) Establishes a paradigm for 
investigating frequently overlooked host-tumor-drug interactions. 
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CHAPTER 1.    INTRODUCTION 
 
 
Target Focused Therapies in New Era Oncology and Road to Cure 
 
Ongoing efforts to understand critical signaling pathways that undergo 
deregulation during tumorigenesis identify specific oncogenes and driver mutations 
integral for the sustenance and proliferation of various cancer types [1-2]. The 
development of agents that modulate such key molecular targets should improve patient 
tolerance and cure rates over conventional non-specific chemotherapy by selectively 
killing cancer cells [1-3]. 
 
 
Trends of Drug Discovery Industry in Post-imatinib Era 
 
 Imatinib (Gleevec by Novartis) is the first example of a cancer-specific small 
molecule inhibitor that was ever approved for clinical use, in particular to treat human 
CML. Initial clinical success of imatinib in dramatically controlling the previously poor 
outcome CML marked a paradigm shift in our approach to anti-cancer therapy and 
jump-started drug discovery efforts against an ever-growing list of validated molecular 
targets in other cancers [4-8]. Since then, remarkable progress has been made in the field 
of target focused drug discovery [9-11] especially for agents that particularly inhibit 
deregulated receptor or non-receptor kinase proteins [8, 10-14], similar to imatinib, and 
are commonly referred to as kinase inhibitors (KIs). The fast-pace development of KIs is 
facilitated by the chemically druggable structure of kinase proteins, advances in 
computational modeling, medicinal chemistry and high throughput biophysical assays 
that compare binding of chemicals against normal and deregulated kinases [5, 15-20]. 
Current automated drug pipelines against diverse kinases and non-kinase targets generate 
hundreds of potential leads, providing tremendous hope to patients suffering from diverse 
leukemias and solid tumors worldwide [5, 9-10, 14, 21]. 
 
 
Current Clinical Status of Target Focused Drugs in Oncology 
 
Rational target focused drug discovery has tremendously decreased the total time 
required between the initial identification of a potential agent and its actual testing in 
cancer patients. Within the last decade, multiple cancer-selective drugs and biological 
agents have been formally approved and many more are being evaluated in clinical trials, 
namely against CML, Ph+ ALL, gastro-intestinal stromal tumors, non-small cell lung 
carcinoma, melanoma, sarcoma, renal cancers etc. However, the majority of 
cancer-selective agents often induce suboptimal primary responses and offer meaningful 
benefit in only a sub-set of cancer patients, which frequently lasts only for a short period 
of time [7, 9-10, 12, 14, 22-23]. Most frustratingly, all current agents which kill the 
respective cancer cells with potent selective activities in vitro, invariably fail to eradicate 
the same cancer cells expressing intact molecular targets in human patients [7, 9-10, 12, 
14, 22-24]. As a consequence, many pre-clinical agents have failed to produce 
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meaningful long-term clinical benefit to the majority of patients despite expected 
pharmacodynamic changes in the intended molecular targets in vivo [7, 9-10, 12, 14, 22-
24], and as a consequence, a few agents have been completely dropped. Since negative 
results are often not reported, the number of such failed agents is bound to be much 
higher. 
 
Paradoxical clinical (in vivo) drug-resistance observed against available cancer-
selective agents in general, remains poorly understood. It likely stems from our limited 
experience with this modern class of oncology agents and has to be addressed to improve 
long term cancer outcomes. 
 
 
Targeted Therapy against Philadelphia Chromosome-positive  
(Ph+) Leukemias 
 
 From among the available cancer targeting drugs, the most extensive preclinical 
and clinical data is available for imatinib and imatinib-like drugs, primarily for their use 
against a set of leukemias defined by a unique cytogenetic abnormality – Philadelphia 
Chromosome [25-26]. 
 
 
The Philadelphia Chromosome 
 
 The Philadelphia chromosome is the hallmark of CML and a high-risk subset of 
acute lymphoblastic leukemia (Ph+ ALL). The Philadelphia chromosome arises from a 
balanced translocation between chromosomes 9 and 22 [25-26]. It encodes an abnormal 
fusion protein, BCR-ABL, which plays an essential role in initiating and driving both 
CML and Ph+ ALL [25-26]. The oncogenic potential of BCR-ABL protein arises from 
the constitutive activation of the tyrosine kinase domain (KD) of ABL in the fused 
protein configuration. 
 
 In CML, mainly the p210BCR-ABL isoform is expressed in hematopoietic stem cells 
(HSCs) which are conceptually referred to as leukemia stem cells (LSCs) [27], and in 
both myeloid and lymphoid progeny. Whereas in Ph+ ALL, expression of mainly 
p185BCR-ABL or alternative p210BCR-ABL isoform is restricted to the lymphoid B cell 
lineage, which display robust LSC-like function to both initiate and propagate leukemia 
during serial transplantation assays. 
 
 
Rationale and Agents for BCR-ABL Targeted Therapy 
 
 The required role for BCR-ABL in sustaining Ph+ leukemias, an attribute referred 
to as ‘oncogene addiction’, rationalizes the inhibition of BCR-ABL as an attractive 
therapeutic strategy in patients with CML and Ph+ ALL [25-26]. 
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 The design of imatinib allows it to selectively bind to the KD of ABL and inhibit 
the constitutive tyrosine kinase activity of BCR-ABL fusion protein. Imatinib was 
initially approved against CML alone [28]. Currently, three BCR-ABL–specific kinase 
inhibitors (BCR-ABL–KIs) namely imatinib (first generation), nilotinib and dasatinib 
(second generation) are FDA-approved for use against both CML and Ph+ ALL. First and 
second generation BCR-ABL–KIs differ in their chemical structures, pharmacokinetic 
properties, binding sites on the ABL, potency to inhibit ABL kinase activity, spectrum of 
off-target inhibition of other kinases and associated adverse effects [20]. 
 
 
Outcomes of BCR-ABL Targeted Therapy in CML 
 
 At the time of diagnosis, CML most commonly is detected in its chronic (early) 
phase and less frequently in accelerated or blast (advanced) phase. In most of the CML 
patients suffering from chronic phase of the disease, continuous BCR-ABL–KI 
monotherapy (using imatinib and more recently dasatinib and nilotinib) induces dramatic 
and long-lasting remissions [29-30]. The majority of patients who have received 
long-term treatments with BCR-ABL–KIs show strong leukemia control by cytogenetic 
evaluation [26, 29, 31-32], and similar results are observed in animal models [33]. 
However, almost invariably patients test positive for mRNA transcripts of BCR-ABL 
(approx 97%) [34], indicating that leukemia has not been completely eliminated [31]. The 
dormant leukemia cells which evade eradication by BCR-ABL–KIs in CML have been 
shown to express the characteristic surface markers of LSCs, and have been proposed to 
sustain drug resistant disease, in a fashion similar to HSCs [35-36] and independent of 
BCR-ABL kinase [37]. Discontinuation of BCR-ABL–KI treatment often results in 
clinical relapse and hematopoietic stem cell transplantation (HSCT) still remains 
important modality for treating those patients who have accelerated phase and blast crisis 
CML or those who either do not tolerate or fail/relapse during continuous BCR-ABL–KI 
treatments [38-41]. 
 
 
Outcomes of BCR-ABL Targeted Therapy in Ph+ ALL 
 
 In contrast to the robust cytogenetic and molecular responses in CML patients, 
BCR-ABL–KI monotherapy evokes much weaker and short lasting responses in patients 
with Ph+ ALL [42]. These differences are also appreciated in animal leukemia 
models [33, 43]. Despite receiving continuous BCR-ABL–KI therapy, human patients 
with Ph+ ALL typically carry significantly higher levels of persistent leukemia and 
inevitably relapse within a few months [42]. The relative primary drug-resistance in 
human Ph+ ALL necessitates the addition of several chemotherapeutic agents and HSCT 
in combination with BCR-ABL–KIs [44]. Multi-modality BCR-ABL–KI-combined 
regimens, the current standard of clinical care in Ph+ ALL, improve the remission rates 
but relapses remain common [44-47] with an 18- to 24-month survival rate of 64% and 
an even lower relapse-free survival rate [44]. 
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 The leukemia cells in Ph+ ALL which display poor initial response and evade 
eradication by BCR-ABL–KIs [45-47] express cell surface markers of lymphoid B cell 
lineage [48]. No distinct population of LSCs has been characterized to drive 
drug-resistant populations, unlike CML [35-36, 48]. 
 
 
Deficiencies of Current BCR-ABL Inhibition Therapy 
 
 
BCR-ABL Kinase Domain Mutations Mediate BCR-ABL–KI Drug Resistance 
 
 The most frequently studied mechanism of drug-resistance against BCR-ABL-KIs 
is point mutations that occur within the KD of ABL (BCR-ABLMUTANTS), which is 
common to both CML and Ph+ ALL [49-52]. Mechanistically, the mutations in 
BCR-ABL, especially in the KD, deteriorate the drug-binding and rescue the oncogenic 
kinase from drug-induced inhibition [49-51]. The total number of the distinct ABL KD 
mutations that have been characterized from refractory Ph+ leukemia samples now 
approaches 80 [53]. The spectrum of BCR-ABL mutations that each of the 
BCR-ABL-KIs select in Ph+ leukemias is distinct, but overlapping, with the notable 
exception of the T315I (Threonine to Isoleucine) mutation which confers profound 
cell-intrinsic resistance to all three approved BCR-ABL–KIs. 
 
 Rigorous research efforts are being made to design the next generation agents 
which can mitigate the effect of BCR-ABL mutations on drug-binding and thus achieve 
sustained BCR-ABL inhibition in vivo, as a critical step towards improvement in the 
clinical efficacy of BCR-ABL targeted therapy [17-18]. 
 
 
Primary Drug Resistance against BCR-ABL–KIs Is Independent of BCR-ABL 
Mutations 
 
 According to the long-term and metadata studies, drug-resistant BCR-ABL 
mutations are predominantly absent in: i) Ph+ ALL at the time of diagnosis which 
responds poorly to BCR-ABL–KIs [50-51, 54], and ii) persistent Ph+ leukemias (both 
CML and Ph+ ALL) which evade eradication during the first few months of targeted 
therapy [49-52]. Periodic testing reveals that as high as 50% of the Ph+ leukemia patients 
never test positive for drug resistant BCR-ABL mutations. Mutations in the ABL KD 
when detected for the first time are quantitatively present as a minority leukemia 
sub-population. Frequency and population size of mutations increases after prolonged 
period of treatment with BCR-ABL–KIs [50-52, 54]. On the other hand, ABL KD 
mutations can spontaneously regress in patients when the BCR-ABL–KI is changed, 
implicating BCR-ABL inhibition in the selective evolution of drug-resistant mutations.  
 
 Thus, primary clinical drug resistance against BCR-ABL–KIs occurs in the 
absence of well characterized ABL KD mutations, and likely plays an instrumental role 
in overall therapeutic failures [49-52]. 
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Ph+ ALL Faithfully Captures the Deficiencies of Targeted Therapy 
 
 Approved BCR-ABL–KIs potently inhibit the KD of ABL protein in biochemical 
assays and in vivo [55] and commit Ph+ leukemia cells to death in vitro [56]. In stark 
contrast, due to unknown reasons, BCR-ABL–KIs fail to completely eliminate leukemia 
in patients with Ph+ ALL [42, 44] and CML [31]. While the drug refractoriness mediated 
by ABL KD mutations is common to both CML and Ph+ ALL, poor responses to 
BCR-ABL–KIs during early therapy, when patients carry predominantly non-mutated 
BCR-ABL (BCR-ABLWT) leukemia, are clearly more evident in patients with Ph+ ALL 
compared to CML. 
 
 Thus, Ph+ ALL faithfully captures both the primary and target-acquired (ABL 
KD mutations) mechanisms of therapeutic failures against BCR-ABL–KIs. These 
features qualify Ph+ ALL as an ideal disease system to study and delineate the 
deficiencies of imatinib, nilotinib and dasatinib – the drugs which have played an 
instrumental role in qualifying the use of target focused cancer therapy in clinical 
settings. 
 
Elaboration of the deficiencies of BCR-ABL–KIs may hold general lessons for 
further optimization and development of alternative targeted therapies in other cancers. 
 
 
An Accurate Murine Model System of Human Ph+ ALL 
 
 In generating and validating an accurate model of human Ph+ ALL that 
recapitulates key features of the human disease, we previously demonstrated that 
p185BCR-ABL expression potently synergized with inactivation of the Arf tumor suppressor 
gene (Arf–/–); these two engineered genetic events are sufficient to fully transform murine 
pre-B cells into leukemia-initiating cells (LICs) [43]. The BCR-ABL oncogenic kinase 
potently ‘drives’ the proliferation of primary Arf–/– p185+ pre-B cells in a growth factor 
independent manner, while the loss of Arf function dramatically attenuates oncogene-
induced, p53-dependent apoptosis, confers cellular immortalization and facilitates 
exponential, high-viability growth. In this leukemia model system, the Arf-loss dependent 
phenotype closely matches that associated with engineered loss of the p53 tumor 
suppressor, thus Arf and p53 do essentially function in a ‘linear’ pathway [57-58]. The 
process of BCR-ABL mediated transformation of pre-B cells is dependent upon co-
operation of transcription factors – signal transducer and activator of transcription 
(STAT5) [59] and c-MYC [60-62], a known oncogene. BCR-ABL fusion protein 
phosphorylates the STAT5 protein (pSTAT5) in the cytoplasm which results in its 
dimerization and transport to the nucleus where it binds to specific STAT5 response 
elements in the promoter region of target genes, including c-MYC. 
 
 More recently, this murine Ph+ ALL model was adapted for in vivo luminescent 
imaging to quantitatively monitor leukemic cell dissemination and therapeutic responses, 
using Arf–/– p185BCR-ABL luciferase-expressing (Luc+) pre-B or LICs [57, 63]. As 
described in human Ph+ ALL clinical trials, single-agent dasatinib therapy in this murine 
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model induces transient remissions in recipient mice harboring very high leukemic 
burdens, only to be followed by clinical relapse a few weeks later (i.e. acquired dasatinib 
resistance) which is frequently associated with the emergence of BCR-ABL kinase 
domain mutations in cells recovered from leukemic-infiltrated tissues [57, 63]. However, 
dasatinib-refractory leukemic cells recovered from leukemic recipients at the end of 
‘induction’ (i.e. at the nadir of leukemic burden, after maximal drug response had been 
achieved) infrequently harbored BCR-ABL kinase domain mutations [63], strongly 
implicating that BCR-ABLMUTANT-independent mechanisms initially attenuate dasatinib’s 
ability to fully eradicate this minimal residual disease (MRD). 
 
 
Etiology of Clinical BCR-ABLMUTANT-independent  
BCR-ABL–KI-resistance 
 
 While rigorous studies has been overtaken to study BCR-ABL mutation mediated 
drug resistance [51, 53, 64-65], sparse efforts have been made to address and overcome 
the primary BCR-ABL–KI-resistance which is predominantly BCR-ABLMUTANT-
independent. Primary BCR-ABL–KI-resistance can originate from factors that can 
broadly be classified as either leukemia-extrinsic or leukemia-intrinsic. 
 
 Among leukemia-extrinsic influences, tumor microenvironment [36, 66-67] and 
poor availability of drug in the target tissues can play a role. Though the tumor 
microenvironment can profoundly alter the drug-action against the tumor in vivo, its 
influence is conventionally not addressed during in vitro drug-evaluations [66]. 
Cell-extrinsic soluble factors such as GM-CSF and GM-CSF plus G-CSF in human 
CML, IL3 in myeloid and lymphoid systems, common gamma chain cytokine signaling 
and its family member IL7 in lymphoid pre-B cells, significantly attenuate BCR-ABL–KI 
induced leukemia cell killing [48, 62, 66, 68-69]. This suggests that signaling pathways 
activated by host growth factors can play a role in drug resistance in BCR-ABL driven 
leukemias in vivo. On the other hand, primary chemo-refractoriness may also arise from 
poor drug-availability in specific target tissues that harbor leukemic cells [70-71]. Both 
CML and Ph+ ALL are primarily disorders of hematopoietic tissues and share a majority 
of the sites of spread, namely, bone marrow, lymph nodes, spleen, liver and thymus [26]. 
Unfavorable pharmacokinetic properties, which are inherent to the chemical nature of 
drug, are thus less likely to play an important role in the varied responses to 
BCR-ABL-KI agents in Ph+ ALL and CML. 
 
 Cell-intrinsic drug resistance mechanisms that function independent of BCR-ABL 
mutations include genetic factors, epigenetic changes or altered dynamics of drug import 
and drug efflux that modulate intracellular inhibitor concentrations. Studies by others 
have established that genetic deletions involving the tumor suppressor CDKN2A/B [72-
74], lymphoid transcriptional regulator IKAROS (also called IKZF1) [75-76], PAX5 [73], 
EBF1 [73], cooperate with BCR-ABL in leukemogenesis. These genetic events, which 
are involved in the pathological development of disease, are present at the time of 
diagnosis in a majority of the patients with Ph+ ALL [74-76] but not CML patients. They 
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may also play a role in poor primary responses to BCR-ABL–KIs in Ph+ ALL, but this 
hypothesis remains to be ascertained. 
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CHAPTER 2.    HYPOTHESIS AND SPECIFIC AIMS 
 
 
Problem at Hand 
 
 Elucidation of the mechanisms of resistance against clinically used drugs, 
especially the new era target-selective agents, is integral to improve their efficacy and 
achieve long-term survival in cancer patients. Significantly, primary drug resistance 
against BCR-ABL–KIs in human Ph+ ALL very well represents the clinical dilemma 
shared by a majority of current drugs that selectively target and kill cancer cells in vitro 
but not in vivo. This disparity strongly implicates the modulation of therapeutic response 
of tumor cells within the host microenvironment. 
 
 In contrast to the remarkable susceptibility of BCR-ABLWT cells to 
BCR-ABL-KIs in vitro, patients suffering from Ph+ ALL receive poor and transient 
benefit from BCR-ABL–KI therapy despite the predominant absence of ABL-KD 
mutations at diagnosis and during initial few months of therapy. The poor primary 
responses evoked by BCR-ABL–KI monotherapy necessitates clinical management of 
Ph+ ALL patients with a multi-modality approach, which is often complicated by the 
frequent unavailability of HSCT donors and the toxicity/intolerability of conventional 
chemotherapy and HSCT, especially in the elderly who form majority of the Ph+ ALL 
population. The performance of BCR-ABL–KIs deteriorates even further later during the 
therapy when ABL KD mutations appear in leukemia lymphoblasts, imparting molecular 
drug resistance.  
 
 While wide scientific attention is paid to improve the drug design for tackling 
molecular drug resistance, it appears clinically more relevant to mechanistically 
understand why BCR-ABLWT Ph+ ALL responds poorly and evades eradication by 
BCR-ABL–KIs prior to the development of molecular resistance mediated by KD 
mutations. The unforeseen primary (BCR-ABL mutation-independent) resistance is most 
likely imparted by the tumor microenvironment (leukemia-extrinsic) and/or alternatively 
by changes within the tumor itself (leukemia-intrinsic). We previously reported a role for 
host cytokines of the common gamma chain receptor family in mediating primary 
imatinib resistance [48], but many alternative host-derived growth factors have similarly 
been proposed in BCR-ABL–KI drug resistance [62, 66-69]. Currently, no consensus 
exists for the relative importance of cytokines that control the cellular responses to 
BCR-ABL targeted agents. 
 
 
Goal of the Study 
 
 The central goal of this scientific work was to advance the performance of 
BCR-ABL targeted therapy in Ph+ ALL – a human leukemia that currently has poor 
long-term survival outcomes.  
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Hypothesis 
 
 Defining and countering the factors that confer the poor response to 
BCR-ABL-KIs in patients with non-mutated BCR-ABL (BCR-ABLWT) Ph+ ALL is 
critical to harness the full therapeutic potential of targeting BCR-ABL for improving the 
long-term survival. We hypothesized that – ‘Combination therapy with drugs that are 
active against the Ph+ ALL phenotypes displaying mechanisms of primary drug 
resistance can eradicate leukemias that are refractory to BCR-ABL–KIs in vivo.’ 
 
 
Specific Aims of the Study 
 
 To maximize the likelihood of discovering combination agents that may 
overcome multi-faceted BCR-ABL–KI drug resistance in Ph+ ALL in vivo, we aimed to: 
 
i. Create a rank-order of leukemia microenvironment-based host-cytokine/s for 
imparting primary drug resistance (cell-extrinsic) against current FDA-approved 
BCR-ABL–KI agents in vitro. 
 
ii. Test the most relevant host-cytokine/s from (i) for conferring BCR-ABL–KI-
refractory phenotype in vivo and characterize its associated cell-intrinsic changes. 
 
iii. Screen drug-rich chemical libraries to identify agents that possess in vitro activity 
against Ph+ ALL cells protected by cell-extrinsic host-cytokine(s) (from i and ii) 
and previously known molecular mechanisms (T315I) of BCR-ABL–KI 
drug-resistance. 
 
iv. Test agents (from iii) alone and in combination with dasatinib in our murine 
model of Ph+ ALL. Assess agent’s ability to improve the primary responses to 
dasatinib and eradicate dasatinib refractory persistent disease, as a critical step 
towards their evaluation in patients with Ph+ ALL clinics. 
 
 
Experimental Methodology 
 
 Here, we report efforts to establish a high throughput (HT) cell-based platform 
that captures the dominant cell – extrinsic (host environment imparted) and intrinsic 
(BCR-ABL mutation-dependent) mechanisms of BCR-ABL–KI-refractoriness in Ph+ 
ALL, in order to discover therapeutic agents capable of improving in vivo BCR-ABL–KI 
performance. 
 
 Utilizing Arf-null (Arf–/–) BCR-ABL transformed LICs, which model key 
biological and genetic features of human Ph+ ALL, we developed an assay that evaluates 
drug performance against BCR-ABLWT LICs co-cultured with candidate cell-extrinsic 
cytokines and growth factors. 
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 Following an unbiased screening approach, we identified IL7 as a specific host-
cytokine that conferred primary chemo-refractoriness against all FDA-approved BCR-
ABL–KIs in vitro, and subsequently confirmed these clinically-relevant results in vivo. 
Next, we assayed this drug-resistant phenotype against a library of FDA-approved drugs, 
natural products, and chemical tool compounds. In addition to the identification of many 
clinical anti-leukemic and other chemotherapeutic agents, several novel agents overcame 
the BCR-ABL–KI-resistant phenotype. Testing of combinations of dasatinib with one of 
our most compelling screening hits, the FDA-approved antimalarial drug 
dihydroartemisinin (DHA), eradicated the residual pool of dasatinib-refractory leukemia 
in vivo. This treatment protocol durably cured 90% of treated animals. This opens up a 
promising therapeutic avenue for treating human Ph+ ALL patients by adding DHA to 
current dasatinib regimens, at the time of diagnosis. 
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CHAPTER 3.    MATERIALS AND METHODS 
 
 
Production and Culture of Murine Leukemia-initiating Cells (LICs) 
 
 Replication-defective mouse stem cell virus (MSCV) retroviral vectors 
coexpressing either wild-type (WT) allele of human p185BCR-ABL or mutant BCR-ABL 
alleles, namely p185T315I or p185F317L, and either green fluorescent protein (GFP) or 
luciferase, were packaged into replication-incompetent ecotropic virions [43, 48, 63]. 
Whole bone marrow cell suspensions from Arf–/– young adult mice were transduced to 
produce Arf–/– p185+ pre-B cells [43, 63]. After initial establishment on autologous 
stromal cell layers over 7 days, transformed pre-B cells were briefly expanded in the 
absence of a stromal layer for 2 days in liquid culture in BCM10 media (RPMI1640 
supplemented with 10% Hyclone fetal calf serum, 4 mM glutamine, 100 Units/mL 
penicillin, 100 μg/mL streptomycin, and 55 μM beta-mercaptoethanol) [48], and 
cryopreserved as 40 identical vials per cell line, generating a master cell bank. Arf–/– 
p185WT and Arf–/– p185T315I pre-B cells (BCR-ABLWT LICs and BCR-ABLT315I LICs, 
respectively) from the cell bank were thawed and allowed to recover in BCM10 for 3 
days, prior to their use in any in vitro or in vivo assays. 
 
 MSCV-IRES-GFP retroviral vectors expressing human c-Myc or empty ‘control’, 
and MSCV-IRES-GFP or MSCV-IRES-RFP retroviral vectors expressing previously-
validated mutants of IKAROS (either IK6 or IK1) [75] or constitutively active (CA)-
STAT5 mutants [77], were utilized to transduce BCR-ABL-expressing LICs, and 
cultured for 48 in BCM10 media before use in drug competition assays. 
 
 
In Vivo Adoptive Leukemia Transfer Model of Ph+ ALL 
 
 Mice were housed in an American Association of Laboratory Animal Care 
(AALAC)-accredited facility and treated on Institutional Animal Care and Use 
Committee (IACUC)-approved protocols in accordance with NIH guidelines. LICs were 
injected into tail veins of healthy, non-conditioned, immune-competent 10- to 12-week-
old IL7+/+ or IL7–/– C57Bl/6J mice (Jackson Labs, Bar Harbor, ME). Animals were 
observed daily and were sacrificed when moribund (dehydration, ruffled fur, poor 
mobility, respiratory distress). Survival curves were generated using GraphPad Prism 
Version 5.0 (La Jolla, CA). Mantel-Cox test was applied to pair-wise comparisons of 
survival data. 
 
 
FACS Assessment of Viability 
 
 Viability of LICs was estimated after counterstaining approximately 5 x 105 LICs 
(in 0.5 mL volume) with 35 μL of a propidium iodide (PI) solution (0.25 mg/mL in PBS). 
The percentage of viable cells was calculated by electronic gating on PI-negative cells on 
PI versus forward scatter dot plots, with forward scatter signals consistent with LICs, and 
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comparison of this number with total cell number. Data were collected and analyzed on a 
BD Biosciences LSR II flow cytometer (San Jose, CA), using BD Biosciences FACS 
DiVa software. 
 
 
FACS Assessment of Cell Cycle Percentages 
 
 For determination of percentages in cell cycle phases, 5 x 105 LICs were 
centrifuged, washed once with PBS, recentrifuged, and cell pellets were resuspended in 
0.5 mL PI staining solution (0.05 mg/mL PI, 0.1% sodium citrate, 0.1% Triton X100), 
which lysed the cells and stained nuclear DNA with PI. Samples were then treated with 
DNAse-free RNAse (0.2 mg/mL in 10 M Tris-HCl/15 mM NaCl, pH 7.5) for 30 min at 
room temperature, filtered, and analyzed for red fluorescence from a PI-labeled DNA on 
BD Biosciences FACS Calibur flow cytometer (San Jose, CA) by using BD Biosciences 
CellQuest Pro software. The percentages of cells within each cell cycle phase were 
computed using the computer program ModFit (Verity Software House, Topsham, ME). 
 
 
Development of LIC-based Multimodality Screening Assay 
 
 Before use in any assay, LICs from the master cell bank had to pass the following 
quality control parameters: test thawing (benchmark: 95% viability at 24 h); PCR 
genotyping to confirm Arf–/– status [78]; mycoplasma testing (negative by Takara Bio 
Mycoplasma PCR assay, Clontech, Madison WI); sequence verification of BCR-ABL 
allele [79]; and in vitro dasatinib sensitivity. 
 
 Maximum DMSO concentration tolerated by LICs in culture was determined to 
be 0.2% (by volume) and was always maintained ≤0.1 % (by volume). LICs plated in 
384-well plates at a cellular density of 5 × 104 per mL in BCM10 were confirmed to give 
exponential and reproducible growth during the first 72 h (Figure 3.1). To select assay 
reagents, 3 high throughput screening (HTS) relevant cellular assays were evaluated 
according to manufacturer’s instructions (Figure 3.2), and flow cytometry analysis was 
performed in parallel (as a reference control) using a high-throughput sampling device 
(Hypercyte by Intellicyte Corporation, Albuquerque, NM) and BD Biosciences LSR II 
flow cytometer (San Jose, CA). Relative to accuracy of high throughput flow cytometry 
(HT-flow) to detect low number of viable LICs, especially at high drug concentrations, 
the luminescent CellTiter-Glo (CTG)-assay by Promega Madison, WI, outperformed a 
common spectrophotometry-based methane-thiosulfonate-based (MTS) reagent 
(CellTiter 96® AQueous One Solution Cell Proliferation assay; Promega Madison, WI), 
and alamar blue (not shown). Since CTG-assay monitors LIC proliferation by using total 
ATP content as a surrogate marker, it inherently cannot distinguish between genetically 
distinct sub-populations within the same well. To adapt the evaluation of cell-intrinsic 
genetic factors into our drug screening platform, cell-mixtures of Arf–/– BCR-ABLWT-RFP 
LICs and Arf–/– BCR-ABLT315I-GFP LICs were treated with dasatinib (Figure 3.3) and 
HT-flow assay performed after 72 hr drug exposures. HT-flow (drug-challenge 
competition assay) correctly detected the expected dasatinib-induced selective
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Figure 3.1. Comparison of the growth properties of Arf–/– p185WT (filled symbols) 
and Arf–/– p185 T315I pre-B (empty symbols) populations during in vitro cell culture. 
 
Both cell types were plated at multiple (eight) cell dilutions (n=3 for each condition, 
time=0 h) in 6-well plates and serially followed daily for 5 days to evaluate absolute 
viable cell count, total viability, doubling times, and total population doublings, using the 
Beckman Coulter cell counter (trypan blue staining) and fluorescence-activated cell 
sorting (FACS) analysis in parallel. Both cell types had identical growth properties. Only 
the comparison for population doubling time in hours (+/– sd) for 3 relevant plating 
densities is presented. FACS cell-cycle analysis confirmed that a population doubling 
time less than 14 h was sufficient to maintain cells in exponential growth (>50% cells in 
S-phase). 
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Figure 3.2. Optimization of the high-throughput LIC-based phenotypic assay. 
 
Arf–/– BCR-ABLWT LICs plated at 5 × 104 per mL were challenged with 6 log-fold 
concentration range of dasatinib or DMSO in 384-well microplates. After a 72 h drug 
challenge, LIC growth was measured by 3 cellular readouts: CellTiter-Glo (CTG)-assay 
(ATP content), MTS assay (viability), and flow cytometry (total viability and viable cell 
counts by DAPI exclusion) in high-throughput (HT-flow) mode. Measured assay 
readouts at various drug concentrations (x-axis) were normalized to DMSO-treated LICs 
and graphed (+/– sd) on y-axis. Total viable LIC counts were determined by FACS, 
reflecting dasatinib-induced phenotypic changes across a 6 log-fold drug-concentration, 
were closely paralleled by the CTG cellular assay output but not by the commonly used 
MTS assay. 
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Figure 3.3. Optimization of HT-flow output to perform drug competition assays. 
 
(a) Arf–/– BCR-ABLWT LICs and Arf–/– BCR-ABLT315I LICs were mixed in 1:1 ratio at 
time t=0 hrs and treated with dasatinib under optimized assay conditions. Schematic of 
BCR-ABL alleles in LICs is presented. (b) Schematic of set-up of flow cytometry 
analysis at t=72 hrs (c) Change in ratio of BCR-ABLWT LICs to BCR-ABLT315I LICs in 
response to increasing drug concentration at t=72 hrs. Real experimental data are plotted 
for dasatinib (n=3) and a hypothetical drug X that is T315I selective is depicted for 
comparison. 
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enrichment of Arf–/– BCR-ABLT315I LICs within the same well. Thus, HT-flow assay 
complements the CTG-assay readout by quantifying the impact of ‘engineered’ 
cell-intrinsic change towards drug refractoriness within the same well. Of the two, 
CTG-assay is easy to use in HTS process (add and read one-step assay with no prolonged 
incubation step required between reagent addition and assay readout), has 10000 fold 
dynamic range, measures IC50 shifts of ≤ 2 fold for dasatinib, displays minimal drift or 
edge effects and robust inter-plate and inter-day reproducibility. 
 
 
Forward Cytokine Phenotypic Screen and Other In Vitro Cellular Assays 
 
 Lyophilized murine and human recombinant cytokines (R&D Systems, 
Minneapolis, MN) were diluted with 1 mg/mL BSA in sterile PBS to a final 
concentration 20 μg/mL and stored at 4oC. Anti-leukemia drugs, BCR-ABL–KIs and 
non-BCR-ABL-specific compounds (LC labs, MA and Sigma, MO), were solubilized in 
DMSO to obtain 10 mM stocks concentrations. Subsequent serial titrations were prepared 
using DMSO in 0.5 mL vials or 384-well drug master plates, and stored at –20oC.  
 
 To study the impact of murine cytokines on dasatinib action, LIC stocks 
containing different concentrations of candidate cytokines were prepared in multi-
channel sterile reservoirs and plated into 384-well plates manually using handheld 
Finnpipette® Novus (Thermo Scientific, Waltham, MA) electronic 16 channel pipette. 
Drug delivery to cell suspensions with a V & P Scientific (San Diego, CA) pin tool and 
all subsequent steps of the CTG-assay were performed under optimized automated 
conditions, as described in Table 3.1. In a forward candidate approach, evaluation of 
IL7’s ability to attenuate drug-induced cell killing and growth inhibition was later 
extended to all BCR-ABL–KIs and non-BCR-ABL specific drugs using the CTG-assay 
in semi-automated mode (non-automated cell-plating as described above). 
 
 Human SUP-B15 Ph+ ALL cells (DSMZ cell culture collection, Germany) in 
McCoys media containing 20% fetal calf serum and penicillin/streptomycin (Invitrogen, 
Carlsbad, CA), were plated at 12,500 cells in 25 μL per well in black clear-bottom 
384-well microplates. Drugs were transferred by pin-transfer. After 72 h incubation at 
37°C, 20% (by vol) MTS assay reagent was added. Microplates were incubated for 75 
min at 37°C, and read colorimetrically at 490 nm. 
 
 
Drug/Cytokine Washout and Cytokine Recovery Studies 
 
 For washout studies, BCR-ABLWT LICs were diluted to a density of 1 × 105 
LICs/mL in BCM10 containing no or 5 mg/mL IL7, and treatment with either dasatinib 
or 0.1% DMSO by volume (non-drug treated controls) was initiated at time 0 h in 
triplicate 100 mm petri dishes. Daily monitoring for expected drug-induced changes was 
performed by naked-eye microscopy from 0 to 72 h. At the 72 h time point, after 
harvesting under identical conditions, total LIC density and viability percentage for all 
samples were determined using Beckman Coulter Vi-cell (trypan blue) in triplicates. 
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Table 3.1. Steps in optimized high-throughput screening assay (CTG readout). 
 
Step Parameter Value Description 
1 Plate cells 25 μL Plate LICs 5 x 104 per mL (25 μL/well) in BCM10 + 0.85 ng/mL IL7 into 384-well 
opaque bottom white microplates using Wellmate (Matrix) 
2 Primary drug 
screening controls 
in columns 1-2 and 
13-14 
25 nL 
 
1A-1I: Nine dasatinib concentrations (100 nM, 30 nM, 10nM, 3 nM, 1 nM, 0.3 nM, 
0.1 nM, 0.03 nM and 0.01 nM) – control for IL7- and BCR-ABL mutation-imparted 
resistance against BCR-ABL–KIs 
2A-2I: Nine staurosporine concentrations (300 nM, 100 nM, 60 nM, 30 nM, 10 nM, 6 
nM, 3 nM, 1 nM, 0.6 nM) – non-BCR-ABL-specific reference control in the presence 
of IL7 
13A-13P, 1J, 2J: DMSO 0.1% (Max Signal OR Negative Control); 14A-14P: 
staurosporine at 300 nM (Min Signal OR Positive Control); 1K-1P, 2K-2P: 40 μM 
dasatinib 
 Secondary drug 
screening controls 
in columns 21-24 
25 nL 21A-21P: DMSO 0.1% (Max Signal); 22A-22P, 23K-24P, 24K-24P: staurosporine at 
300 nM (Min Signal) 
23A-23J: Staurosporine – 10 log-fold dilutions (3 μM to 0.3 pM) – non-BCR-ABL-
specific reference control in the presence of IL7 
24A-24J: Dasatinib – 10 log-fold dilutions (1 μM to 0.1 pM) – control for IL7- and 
BCR-ABL mutation-imparted BCR-ABL–KI drug-resistance 
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Table 3.1. Continued. 
 
Step Parameter Value Description 
3 Add test 
compounds in 
columns 3-12 and 
15-24 in primary; 
columns 1-20 in 
secondary screen 
25 nL Primary screening: Single final drug concentration of 10 μM 
Secondary screening: Triplicate ten half-log serial dilutions (5 μM to 2 nM final 
concentration) of primary screening hits to determine their half-maximal inhibitory 
concentrations (IC50) against LICs 
384-well master drug-stock plates prepared at 1000X in DMSO. Drug delivered to 
assay plates by pin transfer (using V&P Scientific pin tool, 10H pins), giving a final 
drug concentration of 1× and 0.1% DMSO in all control and test wells of assay plates 
4 Incubation 1 72 h Liconics incubator, 8%CO2, 37oC (standard LIC culture conditions) 
5 Incubation 2 20 min Room temp, low light (instructions as per Promega) 
6 Add reagent 25 μL CellTiter Glo (Promega) pre-equilibrated to RT before use 
7 Incubation 3 25 min Room temp, low light (per Promega) 
8 Assay readout ATP 
levels 
Envision, Luminescent mode – ATP levels as a measure of LIC number and viable 
growth in 72 h – Signal measured in RLUs 
9 Data processing Pipeline 
Pilot 
% inhibition by test compound = 100 * (Log10 Test Signal mean – Log10 Min Signal 
mean)/(Log10 Min Signal mean – Log10 Max Signal mean)                                       
Z-prime (Z’) = 1–[(3*stdev of Log10 Max Signal + 3*stdev of Log10 Min 
Signal)/(Log10 Max Signal mean – Log10 Min Signal mean)] Z’is a dimensionless 
metric to assess assay quality – for a good assay Z’≥0.5, and for a perfect assay Z’=1 
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Each sample was spun down in 50 mL BD Falcon™ tubes; the supernatant was discarded 
and LIC pellet resuspended in freshly prepared BCM10 (not containing any cytokine or 
drug). This washing step was repeated 4 times to ensure complete removal of the drug 
and/or cytokine. After the last wash, each pellet was resuspended to 1 × 106 total LICs 
per mL master stocks. Aliquots from master stocks were taken for (i) flow assessment of 
viability and cell cycle percentages (as described above); (ii) manual CTG-assay using 25 
μL sample per well in 384-well microtiter plates (in triplicates), as an independent 
determination for LIC growth. For assessment of extracellular cytokine on recovery of 
LICs that were previously challenged with dasatinib (0 to 72 h), washed master stocks 
were diluted to 5 × 105 total LICs per mL in BCM10 with or without 5 ng/mL IL7, plated 
in 6 well plates (10 cm2 approx.), and incubated at 37°C from 72 to 144 h for recovery, 
during which time daily naked-eye microscopic examinations were performed. At 144 h, 
for each sample total LIC density and viability percentage assessment by Beckman, 
viability and cell cycle percentages by flow assessment and independent CTG evaluations 
were performed as described for the 72 h time point. Trends in cell were also measured 
by CTG readout and used to independently corroborate the findings from trypan blue 
(Beckman) and DAPI staining (FACS). Total viable LICs in a sample were calculated as 
a product of absolute LIC count determined by Beckman and absolute sample viability 
determined by FACS analysis. 
 
 
Dasatinib Re-challenge Studies  
 
 Further studies were performed to evaluate the possibility of a genetically 
drug-resistant subpopulation that could undergo selection with dasatinib/IL7 co-treatment 
during 0-72 h of dasatinib/cytokine washout studies above. To this aim, BCR-ABLWT 
LICs were treated with 100 nM dasatinib or 0.1% DMSO in the absence or presence of 5 
ng/mL IL7 in 100 mm dishes from 0-72 h, as described above; in addition, a dasatinib 
challenge (first-time challenge) across 6 log-fold concentration in the presence or absence 
of 5 ng/mL IL7 was also performed using CTG-assay during this time period (0-72 h). At 
72 h, dasatinib/IL7 co-treated LICs from 100 mm dishes were washed (as described 
above) and immediately challenged (second challenge or re-challenge) with six log-fold 
concentration range of dasatinib in 384-well microtiter plates either in the presence or 
absence of 5 ng/mL IL7 from 72 to 144 h. At 144 h, CTG-assay was performed. 
 
 
High-throughput (HT) Phenotypic Drug Screening 
 
 Minimal concentration of IL7 that conferred near-maximal drug resistance against 
dasatinib, nilotinib and imatinib in BCR-ABLWT LICs was first determined by 
performing cytokine titration assays (0.85 ng/mL IL7) under semi-automated mode and 
later confirmed to reproduce results under fully-automated HT screening conditions 
(Table 3.1). Primary single-point (10 μM) HT evaluation of 5600 compounds (3200 
unique) and subsequent secondary drug screens across 10 two-fold drug dilutions were 
performed. In addition to BCR-ABLWT and BCR-ABLT315I LICs, secondary drug-screens 
were also performed against BCR-ABLF317L LICs, another clinically-known dasatinib-
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resistant ABL KD mutation which gave identical results to that for BCR-ABLT315I (not 
shown). To track the quality of screening experiments, multiple control assay plates were 
set-up during all screening runs to allow for inter-plate and inter-day comparisons at 0, 
24, 48 and 72 hrs. 
 
 
Description of Chemical Library Screened 
 
 The screening library consisted of 5600 (approximately 3200 unique) approved 
drugs and chemicals with known biological activity (bioactives). The library was 
assembled from 3 commercial suppliers: Microsource, Prestwick, and Sigma. The 
Microsource compounds included the following: (a) the Spectrum collection, which 
contains 2000 biologically active and structurally diverse compounds, including known 
drugs, experimental bioactives, and pure natural products [80-81]; (b) the US Drug 
Collection, which contains 1040 drugs that have reached clinical trials in the US and have 
been assigned USAN or US Pharmacopeia status; and (c) the Killer collection, which 
contains a reference set of 160 synthetic and natural toxic substances 
(http://www.msdiscovery.com/index.html). The Prestwick compounds include 1120 
small molecules selected for high chemical and pharmacologic diversity. Ninety percent 
of the collection is composed of known marketed drugs, and the remainder includes 
bioactive alkaloids or related substances. Human bioavailability and human toxicity data 
are available for most compounds (http://www.prestwickchemical.fr/index.php?pa=26). 
The Sigma LOPAC1280 (Library of Pharmacologically Active Compounds) collection 
reflects the most commonly screened targets in the drug discovery community, including 
marketed drugs, failed development candidates, and "gold standards" that have 
well-characterized activities (http://www.sigmaaldrich.com/chemistry/drug-
discovery/validation-libraries.html). 
 
 
Data Processing, Quality Control and Hit Scoring Criteria  
for HT Drug Screens  
 
 All data processing and visualization was performed using custom programs 
written in the Pipeline Pilot platform (Accelrys, v.7.5) and the R program 6.6 [82-83]. 
The R drc package was used to fit sigmoidal curves [83]. ROC statistics were computed 
using the ROCR package [84]. 
 
 The quality of the drug-screening studies against BCR-ABLWT and BCR-
ABLT315I LICs was evaluated by multiple methods including, but not limited to, the 
identification of known antileukemic agents, identification of multiple compound 
replicates intentionally included in the 5600 collection, evaluation of control assay plates, 
and Z’ (see Table 3.1)and other screening quality metrics. In the screening experiments, 
all assay plates demonstrated attenuation of dasatinib potency in the presence of IL7 or 
BCR-ABL mutation. An empirically determined, statistically significant but liberal 
cut-off of >10% activity was chosen to include agents of relatively lower activity 
considering the high-risk nature of Ph+ ALL, the drug-rich nature of the library as well as 
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to allow for a more complete structure-activity relationship and therapeutic class analysis 
after subsequent potency determination through secondary screening. 
 
 The discriminatory power of the phenotypic assay was assessed using receiver 
operating characteristic (ROC) statistics. A total of 165 compounds were selected to 
sample the primary assay according to the distribution of observed activities. ROC curves 
were generated and area under curves (AUCs) calculated to determine the discriminatory 
power of the assay for BCR-ABLWT and BCR-ABLT315I LICs, respectively. 
 
 The activity class designations were assigned based on the curve score and visual 
inspection of dose-response curves (see supplemental data in Appendix). The curve score 
is a 4 character code derived from the following heuristic: 
 
 First character: letter (A,B,C or D) indicating curve quality 
 D = less than 2 points above the noise (defined as outliers from the negative 
control population) 
 C = r2 < 0.50 or range > 200% or EC50 > maximum concentration tested 
 A = r2 > 0.80 and difference between two last points < 10% (indicating 
saturation) 
 B = not A,C, or D 
 N prefix = activity decreases with increase concentration 
 Second character: number (1-6) indicating potency 
 1 = EC50 < 0.1 μM 
 2 = 0.1 μM ≥ EC50 < 1.0 μM 
 3 = 1.0 μM ≥ EC50 < 10.0 μM 
 4 = EC50 > 10.0 μM 
 5 = all C and D curves are assigned 5 
 Third character: number (1-6) indicating efficacy 
 1 = 75% ≥ range < 200% 
 2 = 50% ≥ range < 75% 
 3 = 25% ≥ range < 50 
 4 = range < 25% 
 5 = all C and D curves are assigned 5 
 Fourth character: number (1-6) indicating hill slope 
 1 = hill ≤ 2 
 2 = 2 < hill ≤ 4 
 3 = 4 < hill ≤ 8 
 4 = hill > 8 
 5 = all C and D curves are assigned 5 
 
 A complete list of all compounds evaluated in the secondary drug-screening 
experiments with their structure, supplier information, synonyms, EC50 values, and 
therapeutic classification is reported in the supplemental data in Appendix. 
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Cluster Analysis of Hits Using Therapeutic Classes 
 
 The therapeutic cluster graph was generated by first assigning each compound an 
Anatomical Therapeutic Chemical Classification System (ATC). This classification 
system groups drugs into a 5 level hierarchy according to therapeutic indication and 
chemical properties. The first level indicates anatomical main group and consists of 1 
letter; the second level indicates therapeutic main group and consists of 2 digits; the third 
level indicates therapeutic or pharmacological subgroup and consists of 1 letter; the 
fourth level indicates chemical, therapeutic or pharmacological subgroup and consists of 
one letter; and the fifth level indicates the chemical substance and consists of 2 digits. 
The resulting 7 characters constitute an ATC code, and a compound can be assigned 
multiple ATC codes. ATC codes can be depicted as a network graph by defining a node 
to represent each level in the ATC code and then connecting nodes according to parent-
child relationships (e.g., first-level node A is the parent of second level nodes A01, A02, 
etc.). Compounds without an ATC code were assigned based on similarity to known 
agents, or were assigned to custom codes located under the parent V99 (labeled as “Not 
defined in ATC”). The frequency of ATC Level 1 and Level 2 codes among the 706 
compounds submitted to dose-response analysis was determined. 
 
The resulting network was visualized in Cytoscape (v 2.8.1) using the yFiles 
circular layout algorithm [85]. 
 
 
Evaluation of Hits for Tolerance in Human Patients and Selectivity for MYC Gene 
Expression in Their Mechanism of Drug Action Using Public Databases  
 
 Searches in Pubmed and MetaDrug™ software (by Genego, CA) [86] were 
performed for validated phenotypic hits to document approved use/uses in human 
disease/s if any, and known/predictive toxicity data in human and animal models, 
especially lymphotoxicity.Hits with favorable toxicity profiles were priortized using a 
previously described statistical analysis [87-88], similar to the COMPARE algorithm [89-
91], that evaluates National Cancer Institute (NCI) anti-cancer drug screening data. 
Briefly,the publically available databases containing half-maximal growth-inhibitory 
concentrations (GI50) of approximately 4444 common chemicals and FDA-approved 
drugs against NCI60 panel of 60 human cancer cell-lines (of 9 different tissues of origin) 
and complete gene expression datasets of all NCI60 cell lines, were accessed from the 
developmental Therapeutics Program (DTP) website (http://www.dtp.nci.nih.gov) and 
(http://discover.nci.nih.gov/cellminer/), respectively. A correlation analysis was 
performed between GI50 values and c-MYC expression across NCI60 cell lines for i) 
phenotypic hits demonstrating significant potency in a secondary screen, (whenever 
available in the DTP database, using NSC number as chemical identifier), ii) dasatinib, as 
a control for BCR-ABL–KI drug family, and iii) 4444 commonly used non-BCR-ABL–
KI DTP agents (to achieve statistical power and compute p values).  
 
 To extend the mechanistic understanding on DHA drug action against human 
cancer cells, a subset of DHA-senstive NCI60 cancer cell lines was identified. Using 
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complete affymetrix data set from Cellminer™ website, the expression of each gene 
across the DHA-sensitive cell lines was subjected to correlative analyses with paired GI50 
values of DHA. Pearson coefficient of correlation computed for individual genes was 
used to generate a rank order for all genes. A probeset of top 40 positively correlated 
genes was selected, representing a distinctive drug-sensitivity signature for DHA across 
human cancer cell lines. The expression level of this gene-set was then compared 
between murine LICs and primary Ph+ ALL leukemic samples, obtained from seven 
patients at the time of diagnosis (GSE17459, Pubmed). Cross-species correlative analysis 
was performed for each of the 40 genes by both expression values and rank order. 
 
Gene expression signature of IL7-induced dasatinib resistance in LICs was 
compared with DHA senstivity signature across NCI60 panel to select overlapping genes 
which plausibly may play a role in overcoming dasatinib resistance. 
 
 
In Vivo Preclinical Therapeutic Studies 
  
 For in vivo use, dasatinib (LC Labs, Woburn, MA) in citric acid (pH 3.1) [92], 
and DHA (Avachem, San Antonio, TX) in 0.5% carboxy-methylcellulose/0.5% Tween 
80/0.5% benzyl alcohol, were administered by oral gavage. In toxicity studies (data not 
shown), DHA up to 300 mg/kg given as a single or split dose for ≤ 5 days/week over a 
six week time period induced no significant weight loss, lethargy, seizures or deaths 
corroborating published findings [93]. During one or two agent therapeutic studies, 
animal weights were monitored daily (5 days/week) and drug dosing was adjusted 
accordingly. 
 
 
Bioluminescent Imaging to Track Therapeutic Responses In Vivo 
 
 Bioluminescent imaging and analysis was performed using a Xenogen IVIS-200 
system and Living Image software 3.01 (Caliper Life Sciences, Hopkinton, MA), as 
described previously [63]. Total bioluminescent flux measurements (photons/second) 
were quantified over the whole animal body. Recipient mice that remained clinically 
healthy 12 months after terminating therapy and had undetectable bioluminescent signal 
in vivo were designated “long-term survivors.” 
 
 
Analysis of BCR-ABL KD Mutations 
 
 Genomic DNA was extracted with phenol-chloroform from cultured cells, 
hematopoietic tissues, and leukemic-infiltrated meninges from moribund mice during 
therapy. Polymerase chain reactions (PCR) to selectively amplify only the human (and 
not murine) ABL KD were performed using primers as described previously [63, 79]. 
Sequence analysis was performed from 10 to 20 independent bacterial colonies, while 
identified mutations were considered significant if present at ≥ 20% occurrence in 
individually sequenced clones.  
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CHAPTER 4.    RESULTS 
 
 
A BCR-ABL Kinase Domain Mutation Does Not Impart Any Advantage in  
Leukemia Progression In Vitro or In Vivo 
 
 First, to model the clinically most dominant BCR-ABL mutation-dependent 
(molecular) resistance against all BCR-ABL–KI drugs in Ph+ ALL, we generated Arf–/– 
pre-B cells driven with p185BCR-ABLWT or p185BCR-ABLT315I mutant allele, referred 
as Arf–/– BCR-ABLWT LICs and Arf–/– BCR-ABLT315I LICs, respectively. Both LICs 
performed similarly during growth assays in vitro (Figure 3.1) and displayed a potent 
and highly comparable leukemia-initiating capacity in vivo when injected in serial 
limiting cellular dilutions (Figure 4.1). 
 
 Thus, T315I BCR-ABL mutation, which imparts remarkable cell-intrinsic 
molecular drug-resistance, has no impact on leukemia progression in vivo in the absence 
of BCR-ABL–KI-treatment. 
 
 
Cytokine Screen Identifies IL7 as the Main Host Factor That Mediates Primary 
Dasatinib Resistance, Independent of BCR-ABL Mutations 
 
 To address the role of cell extrinsic mechanisms in modulating primary responses 
to BCR-ABL inhibitory therapy in Ph+ ALL, fifteen cytokines normally present in the 
leukemia microenvironment were evaluated for their ability to protect murine Arf–/– 
BCR-ABLWT LICs from dasatinib, the most potent clinical BCR-ABL inhibiting agent 
(Figure 4.2a). Arf–/– BCR-ABLWT LICs were confirmed beforehand to not harbor any 
drug-resistant mutations in the ABL KD. It is important to note that genetically-defined 
Arf–/– BCR-ABLWT LICs are transformed primary pre-B cells that retain phenotypic and 
signaling properties essential for suspended leukemic blasts to respond to the surrounding 
host-environment [48]. These properties are typically not present in established leukemic 
cell lines that have been extensively cultured in vitro. 
 
 Among the cytokines tested, low-level (< 1 ng/mL) IL7 provided the most potent 
and robust protection against dasatinib-induced growth arrest and killing of Arf–/– 
BCR-ABLWT LICs (Figure 4.2a). In addition, Interleukin3 (IL3) [62, 69, 94], thymic 
stromal lymphopoietin (TSLP, an IL7-like cytokine that shares a receptor subunit with 
IL7) [95] and Interleukin4 (IL4) conferred resistance, but much more weakly. In contrast, 
TGFβ enhanced dasatinib activity. 
 
 
IL7 Mediates Primary Drug Resistance against All Approved BCR-ABL–KIs in 
Murine and Human Ph+ ALL Cells, Which Is Completely Reversible 
 
 Next, we extended the evaluation of IL7, our most potent candidate from the 
cytokine screen, to assess its impact on the performance of other drugs, including  
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Figure 4.1. Leukemia stem cell (LSC) function assay by serial dilution and 
implantation comparing the in vivo leukemia-initiating capacity of Arf–/– p185WT 
(left) and Arf–/– p185T315I pre-B (right) populations. 
 
Arf–/– p185-transformed pre-B murine cells are referred as LICs. Kaplan-Meier curves 
represent the overall survival of nonconditioned immunocompetent C57Bl/6J recipient 
mice that received serial log-fold dilutions (n=4 per arm) of LIC-number (as indicated in 
the inset legend) on day 0. 
  
26 
 
 
 
 
Figure 4.2. IL7 confers BCR-ABLMUTANT-independent primary drug-resistance 
against BCR-ABL–KIs in Ph+ ALL. 
 
(a) Radar plot representing the effect of 15 hematopoietic cytokines on dasatinib potency 
(EC50) against Arf–/– BCR-ABLWT LICs. CTG-assay measured LIC killing after 72 h 
dasatinib exposures in presence of increasing concentrations of indicated cytokines. Each 
spoke represents an individual cytokine; each line graph represents dasatinib EC50 (nM) 
at indicated titration of the parent cytokine (see supplemental data in Appendix).  
(b) Arf–/– BCR-ABLWT (triangles) and Arf–/– BCR-ABLT315I (circles) LICs were treated 
with drug or DMSO for 72 h in the absence (blue) or presence (red) of 1 ng/mL mIL7, in 
triplicates. For each drug concentration, LIC growth measured by CTG-assay was 
normalized to DMSO-treated LICs and fit using nonlinear regression (+/– sd).  
(c) Viability of human Ph+ ALL SUP-B15 cells after 72 h drug-treatment in absence or 
presence of 25 ng/mL hIL7, was measured by MTS assay. Values were normalized to 
DMSO-treated cells. (d, e) Kaplan-Meier survival curves showing overall survival in 
IL7+/+ and IL7–/– Bl6 host-mice receiving day 0 tail vein injection of (d) 2×102 Arf–/– 
BCR-ABLWT LICs (vehicle treated), with median survival of 20 days in IL7+/+(n=4) 
versus 33 days in IL7–/– mice (n=4), P=0.0069, or (e) 2×105 Arf–/– BCR-ABLWT LICs. 
Data are an average of 2 independent experiments in which vehicle or dasatinib therapy 
was initiated on day 7 or 9. Survivals of vehicle-treated IL7+/+and IL7–/– mice were 
comparable. Dasatinib treatment caused a median survival of 33 days in IL7+/+ (n=12) 
versus 41 days in IL7–/– (n=11) mice, P=0.0061.  
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BCR-ABL–KIs and non-BCR-ABL inhibiting drugs. IL7 significantly attenuated the 
potency of all FDA-approved BCR-ABL–KIs against murine Arf–/– BCR-ABLWT LICs 
(Figure 4.2b) and the human Ph+ ALL cell line SUP-B15 (Figure 4.2c). In contrast, IL7 
did not affect the potency of tested non-BCR-ABL drugs underscoring the specificity of 
this cytokine protection (Figure 4.3). 
 
 The specificity and dynamic nature of IL7 in mediating primary resistance against 
BCR-ABL-targeting drugs was further confirmed by four in vitro findings. First, 
mechanistic evaluations by FACS analysis revealed dasatinib-induced phenotypic effects 
of G0-G1 growth arrest and apoptosis of Arf–/– BCR-ABLWT LICs were significantly 
blunted by the presence of cell-extrinsic IL7 during drug exposure (Figure 4.4a and b). 
Second, transient pharmacological BCR-ABL-inhibition, achieved by washing out 
drug/cytokine after a period of dasatinib/IL7 co-treatment (see ‘Drug/cytokine washout 
and cytokine recovery studies’ in Chapter 3), dramatically increased the responsiveness 
of Arf–/– BCR-ABLWT LICs to cell-extrinsic IL7 (Figure 4.4a, c and d) [96]. Third, 
removing (washing out) IL7 completely reversed cytokine protection and restored 
dasatinib’s potent activity to kill Arf–/– BCR-ABLWT LICs (see ‘dasatinib re-challenge 
studies’ in Chapter 3, data not shown). Fourth, IL7 significantly rescued the clonal 
outgrowth capacity of single flow-sorted Arf–/– BCR-ABLWT LICs during prolonged 
treatments with dasatinib (Figure 4.5). 
 
 Thus, IL7 imparts primary refractoriness against approved BCR-ABL–KIs in 
murine and human Ph+ ALL cells, which exists as a completely reversible phenomenon. 
 
 
Physiological Levels of Host-expressed IL7 Contributes to an Aggressive, Dasatinib-
resistant Phenotype of Ph+ ALL In Vivo 
 
 We studied the effect of physiologic levels of IL7 on leukemia progression and 
dasatinib responsiveness in vivo. Host IL7+/+ (i.e. wild-type; WT) mice injected with 
2×102 Arf–/– BCR-ABLWT LICs showed more rapid leukemia onset compared to strain-
matched IL7–/– (null) hosts (Figure 4.2d), suggesting that murine Ph+ ALL responds to 
host-IL7 with accelerated progression. Injecting 2×105 Arf–/– BCR-ABLWT LICs 
overcame this trend (Figure 4.2e), suggesting the phenomena is most important during 
the phase of disease establishment. Host-expressed physiologic level of IL7 significantly 
shortened the survival benefit from dasatinib monotherapy of BCR-ABLWT leukemias 
(Figure 4.2e). This finding is the first definitive demonstration of a single host-cytokine 
in inducing BCR-ABL–KI drug resistance in vivo. Of note, terminal clinical presentation 
in IL7-WT host-mice was either with signs of CNS disease (bulging skull, uneven gait, 
erratic behavior) or frank relapse in rest of the body, whereas the majority of IL7–/– host-
mice presented with signs of CNS disease necessitating their sacrifice, consistent with 
reports on low bioavailability of BCR-ABL–KIs in CNS [70-71]. 
 
 From a therapeutic perspective, these findings in combination with our in vitro 
observations support that in vivo responses to dasatinib therapy in Ph+ ALL are 
modulated by cell-extrinsic IL7 in the absence of BCR-ABL KD mutations.   
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Figure 4.3. Comparative evaluation of IL7-mediated protection conferred against 
non-BCR-ABL-specific targeting drugs (top panel) and conventional cytotoxic 
antileukemic clinical drugs (bottom panel). 
 
Arf–/– BCR-ABLWT LICs were treated with indicated drugs or DMSO (no drug) for 72 h 
in the absence (blue) or presence (red) of high (10 ng/mL) murine IL7, in triplicates. The 
antibiotic drug Cefaclor (often used in leukemia clinics) was used as a non-antileukemic 
drug control. For each drug concentration, LIC growth was measured by the CTG-assay 
and average values were normalized to DMSO-treated LICs and graphed (+/– sd). 
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Figure 4.4. Protection of Arf–/– BCR-ABLWT LICs by IL7 during dasatinib 
exposures (0 to 72 h) and in the post-exposure recovery period (72 to 144 h, no 
dasatinib). 
 
See Chapter 3 for details. (a) Total sample viabilities (DAPI staining, FACS) at the end 
of exposure period (dark gray=IL7; light gray=No IL7) and recovery period (red=IL7; 
blue=No IL7). Light gray versus dark gray comparison depicts significant IL7 protection 
during dasatinib exposures. Few LICs surviving dasatinib exposures in the absence of 
IL7 (light gray), later deteriorated and died during recovery period, irrespective of IL7, 
confirming that BCR-ABL inhibitor exposures commit BCR-ABL+ cells to death [56]. 
IL7 significantly improved recovery of dasatinib/IL7 co-treated LICs (red vs blue), 
clearly evident at 1000 nM but not at 100 nM and 10 nM dasatinib concentration because 
of over-confluent growth in presence of IL7 (see (c) and (d)). (b) Cell cycle changes 
(FACS) at the end of exposure period (corresponding to light and gray bars in (a)). 
Incremental dasatinib doses (which cause incremental BCR-ABL inhibition [55]) induced 
cell cycle arrest and apoptosis; IL7 significantly protected LICs from these changes  
(c) Cell cycle analysis at the end of recovery period (corresponding to blue and red in 
(a)). (d) Conditions showing positive LIC growth during recovery period, normalized for 
equal number of LICs plated at start of recovery (dark grey). Ratio of fold LIC-change in 
presence (face-down bracket) to that in absence (face-up bracket) of IL7 increased in 
LICs with higher previous BCR-ABL inhibition from higher dasatinib concentrations 
during exposure period [96]. 
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Figure 4.5. In vitro leukemia clonal outgrowth efficiency assays. 
 
Either 1 or 10 viable Arf–/– BCR-ABLWT LICs per well sorted by single-cell flow 
cytometry into 3 clear-bottom 384-well plates for each condition were treated (t=0) with 
DMSO (0.1 % by volume) or dasatinib in the absence (dark grey) or presence (light grey) 
of IL7 (5 ng/mL). After 8 days of incubation, naked-eye microscopic examination was 
performed. Wells showing significant positive growth (approximately ≥ 50 LICs per 
well) were scored positive and percentage of positive wells for each condition indicated 
on the x-axis was calculated. 
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IL7 Protects against Dasatinib by Strongly Counteracting the Decrease  
in pSTAT5 Protein and c-MYC Expression 
 
 What intra-cellular changes initiated by the host-IL7 are critical for imparting 
primary dasatinib resistance? Arf–/– BCR-ABLWT LICs were briefly (4 h) challenged with 
100nM dasatinib in the presence or absence of IL7 and then evaluated using a 
cell-signaling kit (Luminex® 8-plex kit by Millipore, MA) which detects level of 
phosphorylated (active) form of eight different cell-signaling proteins relevant to cancer 
biology (Figure 4.6a) and gene expression arrays (Figure 4.6b). Comparative 
assessments in the global gene expression and various signaling pathways allowed us to 
detect the intra-cellular changes crucial for mediating IL7-induced dasatinib-
refractoriness. 
 
 Among the eight phosphorylated signaling proteins evaluated, short dasatinib 
exposure in the absence of IL7 decreased the level of mainly pSTAT5 protein (Figure 
4.6a). STAT5 is an established phosphorylation target of uninhibited BCR-ABL kinase 
activity [97-98], and decrease in the level of pSTAT5 is commonly used as a surrogate 
marker of cellular BCR-ABL-inhibition [99-100]. Interestingly, the presence of IL7 
significantly maintained high levels of pSTAT5 in Arf–/– BCR-ABLWT LICs despite 
pharmacological BCR-ABL inhibition by dasatinib (Figure 4.6a) [101]. These findings 
were confirmed using conventional western blotting (Singh and Opferman, unpublished). 
A positive trend was observed between the levels of pSTAT5 protein in Arf–/– 
BCR-ABLWT LIC samples at 4 hours and their respective total sample viability and total 
viable cell counts after 72 hours, as measured by CTG and FACS (compare with Figure 
4.2b and Figure 4.4a, respectively). This suggested a new mechanistic role for pSTAT5 
in IL7 mediated rescue of Ph+ ALL from BCR-ABL inhibitory therapy. 
 
 From gene expression data, we dissected a set of mRNAs that underwent the most 
significant quantitative change in cellular expression due to brief dasatinib exposure in 
the absence of IL7, relative to untreated LICs, to determine a ‘dasatinib response 
signature’ in Ph+ ALL. Using this signature as a reference, we identified a subset of 
mRNAs which were most significantly protected from dasatinib-induced change in 
cellular expression due to the presence of IL7 during drug exposure, referred as 
‘IL7-imparted dasatinib resistance signature.’ Enrichment analysis (Figure 4.6b) of the 
cytokine-mediated dasatinib resistance signature demonstrated that IL7 strongly protects 
cellular expression of c-MYC and c-MYC target genes, with c-MYC being the second 
highest protected mRNA by IL7 (see supplemental data in Appendix). 
 
 Cellular binding of growth factor IL7 activates the receptor-associated 
JAK3-STAT5 signaling pathway [101], resulting in the direct upregulation of c-MYC by 
activated STAT5 (pSTAT5) [102]. Thus, IL7 counteracts the decrease in both pSTAT5 
and c-MYC resulting from pharmacological inhibition of BCR-ABL by dasatinib, and 
recues Arf–/– BCR-ABLWT LICs by initiating IL7-JAK3-pSTAT5-cMYC signaling. 
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Figure 4.6. Mechanistic evaluation of host-IL7 imparted primary resistance 
against dasatinib. 
 
Arf–/– BCR-ABLWT LICs were challenged with dasatinib or DMSO for 4 hrs in presence 
or absence of IL7. (a) Levels of pSTAT5 measured at 4 hrs by Luminex 8-plex 
multipathway kit are presented. Change in level of pErk/MAP kinase 1/2, pSTAT3, 
pJNK, p70 S6 kinase, IkBalpha, CREB, and p38 was statistically insignificant and is not 
shown. (b) Cartoon shows enrichment analysis of ‘IL7 protection gene signature against 
dasatinib’. Increase or decrease in expression of genes by dasatinib alone (no IL7) is 
presented by red (decrease) and blue (increase) color, respectively. Size of the circle 
presents fold-protection against dasatinib-induced change in gene expression due to the 
presence of IL7.Only top representative genes undergoing significant change in the 
presence of IL7 are shown. See supplemental data in Appendix for complete data set. 
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High pSTAT5 and IKAROS Haploinsufficiency Are Candidate Resistance  
Biomarkers with c-MYC as a Convergence Node of Resistance  
against BCR-ABL Inhibitor Therapy in Ph+ ALL 
 
 Our mechanistic studies implicated c-MYC expression in cytokine mediated 
BCR-ABL–KI-resistance. Because IKAROS directly represses c-MYC expression in 
pre-B cells and IKAROS haploinsufficiency relieves such c-MYC repression [103], we 
hypothesized that IKAROS haploinsufficiency by derepressing c-MYC expression may 
also impart cell-intrinsic BCR-ABL–KI-resistance in Ph+ pre-B cells. 
 
 To confirm the role of pSTAT5, c-MYC and IKAROS haploinsufficiency in ABL 
KD mutation-independent drug-resistance, we utilized fluorescent vectors expressing 
constitutively active STAT5 (CA-STAT5) single or double mutants, human c-MYC or 
dominant negative (DN) IKAROS (IK6), imitating constitutive signaling by pSTAT5, 
c-MYC-overexpression and IKAROS haploinsufficiency, respectively (Figure 4.7). 
Analogus to IKAROS-WT, the IK1 mutant binds to the c-MYC promoter and inhibits its 
expression, whereas the IK6 mutant derepresses c-MYC expression [75, 103]. Arf–/– 
BCR-ABLWT LICs transduced (florescent) with these vectors were mixed with parent 
non-transduced (non-florescent) LICs and subjected to drug-competition assays in the 
absence of IL7. HT-flow assay (please refer Figure 3.3) performed on day 2, 3, 5 and 9 
relative to day 0 allowed a temporal assessment of ‘engineered’ cell-intrinsic genetic 
changes on growth and cellular response to dasatinib and imatinib. 
 
 In the absence of BCR-ABL–KI treatment (Figure 4.7a), proliferation of Arf–/– 
BCR-ABLWT LICs expressing GFP-only (‘empty’ vector), IK6 or c-MYC was 
comparable to non-transduced parent LICs, whereas fluorescent Arf–/– BCR-ABLWT LICs 
expressing pre-validated single or double CA-STAT5 mutants or the IK1 mutant [75, 
103], were quickly lost in culture. The later observation corroborated the known essential 
role of c-MYC expression in sustaining Ph+ LICs [60-61]. 
 
 Treatment (Figure 4.7b) of control LIC mixtures with increasing imatinib and 
dasatinib concentrations did not alter the ratio between non-transduced LICs and 
daughter LICs transduced with GFP-only vectors. The total mixture viability (by DAPI 
exclusion) of control LIC mixtures decreased in a dose and time proportionate fashion. 
This corroborated our previous flow-cytometry results (Figure 4.4a), and confirmed the 
overall quality of HT-flow drug-screening runs. In stark contrast to control LIC mixtures, 
drug exposures temporally selected the Arf–/– BCR-ABLWT LICs transduced with vectors 
expressing c-MYC or IK6 or single mutant CA-STAT5 or double mutant CA-STAT5. 
Remarkably, HT-flow counter genetic-screen demonstrated that the degree of LIC-
selection to be quantitatively proportional to BCR-ABL-inhibition achieved by 
incremental BCR-ABL–KI doses (Figure 4.7b and c) [55]. These results were later 
confirmed with western blots (unpublished, Singh and Opferman). Thus, pSTAT5, 
c-MYC and functional-loss of IKAROS, all mediate BCR-ABL mutation-independent 
drug resistance according to proposed model in Figure 4.7d. In a direct test of c-MYC as 
a node for dasatinib-resistance in Ph+ ALL, dasatinib-challenges were performed against 
Arf–/– BCR-ABLWT LICs expressing either an empty vector or c-MYC protein.  
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Figure 4.7. Results of counter genetic screen by HT-flow confirming the role of 
pSTAT5 activity, IKAROS haploinsufficiency and c-MYC over-expression in 
primary drug resistance against BCR-ABL-inhibiting drugs. 
 
Mixtures composed of non-transduced (non-fluorescent) parent p185WTLICs and 
transduced (fluorescent) daughter p185WTLICs expressing protein of interest (as per 
legends) were exposed to (a) no drug (controls) or (b,c) wide-range of imatinib and 
dasatinib concentrations in the absence of IL7, in triplicate wells. Percentage of 
fluorescent (transduced) LICs on day 0, 2, 5 and 9 was measured by HT-flow assay.  
(b) Ratio of average (n=3) number of viable fluorescent (transduced) LICs (by DAPI) on 
day 2, 5 and 9 relative to day 0, at each indicated experimental condition, are shown for 
dasatinib and imatinib. Change in ratio is presented using a three-color graded scale 
(red>1, yellow=1, green<1; dark (red/green) color implies higher change and light 
(red/green) color implies lower change. (c) X-Y line graph representing temporal 
selection (x-axis) of CA-STAT5 double mutant (DM) expressing LICs (relative to day=0) 
due to exposure to dasatinib concentrations, in a dose-response fashion. (d) Proposed 
mechanistic model of BCR-ABL mutation-independent drug-resistance against BCR-
ABL inhibiting drugs in Ph+ ALL. 
 
* Zero values (darkest green) indicate that total sample viability is below the detection-
threshold by flow cytometry. 
 
** Relatively low number of LICs transduced by single and double CA-STAT5 mutants 
on day=0 in (a) due to low transduction efficiency (from day –2 to 0) later allowed 
much higher fold selection within the same wells (from day 0 to 9) in (b). 
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Over-expression of c-MYC resulted in a significant deterioration (100 fold) of dasatinib 
potency (EC50) in a BCR-ABL mutation-independent fashion (data shown later for 
convenience). 
 
 As an independent test of our hypothesis, we examined published biochemical 
profiles of agents for their binding affinity to kinase proteins [20], especially against 
BCR-ABL and JAK3 kinases, the latter being specific for mediating the effects of 
extracellular IL7 to intracellular compartment. Indeed, both dasatinib and nilotinib inhibit 
BCR-ABL at nanomolar concentrations, but were found to completely lack the ability to 
bind and inhibit JAK3 kinase.  
 
 
HT Drug Screens to Identify Agents with Activity against Ph+ ALL Cells Protected 
by Extracellular IL7 and T315I Mutation 
 
 To search for novel agents with potent cellular activity against IL7-induced 
BCR-ABL–KI-resistant phenotypes, we screened 3200 well-annotated and 
mechanistically diverse bioactive agents, which included FDA-approved oncology and 
anti-infective drugs. In the primary screen, Arf–/– BCR-ABLWT LICs and Arf–/– 
BCR-ABLT315I LICs were treated with a single concentration (10 μM) of agents in the 
presence of IL7 (0.85 ng/mL). The quality of the screen was confirmed by receiver 
operating characteristic (ROC) analysis and other statistical metrics (Figures 4.8 to 4.12). 
The 627 compounds showing statistically significant activity (≥ 10% growth inhibition) 
were further augmented with available structural analogs and drugs of the same 
pharmacologic class to yield 706 active compounds. Concentration–response 
relationships were established for these compounds against Arf–/– BCR-ABLWT LICs and 
drug-resistant Arf–/– BCR-ABLT315I LICs in the presence of IL7, giving 229 validated hits 
with reasonable potency. All validated hits were equipotent in inhibiting the growth of 
Arf–/– BCR-ABLWT LICs and Arf–/– BCR-ABLT315I LICs. This set included 15 known 
cytotoxic antileukemic drugs (See supplemental data in Appendix), which enhance BCR-
ABL–KI therapy in vivo [44-45, 63], thus validating the detection of appropriate 
phenotypic responses. Furthermore, cluster analysis (Figure 4.13) indicated that this set 
effectively sampled the space of all existing therapeutic classes (Figures 4.12 and 4.13). 
See supplemental data in Appendix for detailed annotation of all validated hits. 
 
 
A Common Anti-malarial Agent DHA Overcomes Multi-factorial  
BCR-ABL–KI Drug Resistance by Cell-extrinsic IL7 and Cell-intrinsic  
c-MYC Over-expression  
 
 Given that the validated hits that overrode the IL7-protected leukemia phenotype 
contained compounds with varying mechanisms of action (Figure 4.13), and that 
increased c-MYC expression acts as a common node for primary BCR-ABL–KI-
resistance in ‘high-risk’ Ph+ ALL (Figures 4.6 and 4.7), we aimed to select those 
validated hits which may demonstrate selectivity to kill cancer cells with increased 
c-MYC expression and a known favorable toxicity profile in humans.  
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Figure 4.8. Quality control for the primary screen of 5600 agents against Arf–/– 
BCR-ABLWT LICs performed in the presence of 0.85 ng/mL IL7. 
 
See Table 3.1 for well locations. (a) Distribution of EC50 of non-BCR-ABL-inhibiting 
reference compound staurosporine (calculated from wells 2A-2J in (d)). (b) Scatter plot 
of percent activity of the test compounds relative to controls. Good separation is seen 
between negative controls (red, DMSO-treated. max signal, column 13 in (d)) and 
positive controls (green, 300 nM staurosporine, min signal, column 14 in (d)). Test 
compounds showing statistically significant activity relative to background noise 
(negative controls, red) are depicted in blue and inactive test compounds in black. 
Densities for positive, negative, and test compounds are shown on the right. (c) 
Distribution of Z’ values for each plate in the primary screen. All Z’ values throughout 
the run – average=0.82, lowest=0.71 and highest=0.9 (d) Heat map comparison of well 
activity averaged across all plates. Wells 1A-1J and 2A-2J show serial dilutions of 
dasatinib and staurosporine. In presence of IL7, average LIC growth inhibition of approx. 
45% was achieved by 100 nM dasatinib (well 1A), the later approaching maximum 
concentration achieved in human plasma. 
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Figure 4.9. Quality control for primary screen of 5600 agents against Arf–/– BCR-
ABLT315I LICs performed in the presence of 0.85 ng/mL IL7. 
 
(a) Distribution of EC50 of non-BCR-ABL-inhibiting reference compound staurosporine 
(calculated from wells 2A-2J in (d)). (b) Scatterplot of percent activity of the test 
compounds relative to controls. Good separation is seen between negative controls (red, 
DMSO-treated, max signal, column 13 in (d)) and positive controls (green, 300 nM 
staurosporine, min signal, column 14 in (d)). Test compounds showing statistically 
significant activity relative to background noise (negative controls, red) are depicted in 
blue; inactive test compounds are black. (c) Distribution of Z’ values for each plate in the 
primary screen. All Z’ values throughout the run – average=0.85, lowest=0.77, and 
highest=0.92 (d) Heat map comparison of well activity averaged across all plates. Wells 
1A-1J and 2A-2J show serial dilutions of dasatinib and staurosporine tested against BCR-
ABLT315I LICs. Although 100 nM dasatinib (Well 1A) was totally ineffective, well 2A 
with highest staurosporine concentration (300 nM) showed average LIC growth 
inhibition of approximately 100%. 
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Figure 4.10. Primary high-throughput drug screening experiments captured 
BCR-ABL–KI drug-resistant phenotypes with high accuracy. 
 
Distributions of independent dose response curves of dasatinib and staurosporine against 
Arf–/– BCR-ABLWT and Arf–/– BCR-ABLT315I LICs in the presence of 0.85 ng/mL IL7 
calculated separately from all assay plates (wells 1A-1J and 2A-2J) of primary drug 
screening experiments (also see Figures 4.8d and 4.9d) are presented. Both IL7-imparted 
dastinib–resistant phenotype in BCR-ABLWT LICs (EC50 in nM: 95%CI = 86-116, 
average >100) and BCR-ABL-mutation-imparted BCR-ABL–KI-resistant phenotype in 
BCR-ABLT315I LICs, similar to Figure 4.2b, were consistently captured across all plates. 
Low interplate variability in calculated EC50 values was observed for the non-BCR-ABL-
targeting reference compound staurosporine (95%CI for EC50 in nM: WT = 11-12, 
T315I = 15-16) and majority of the validated hits (refer the supplemental data in 
Appendix). 
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Figure 4.11. Receiver Operating Characteristic (ROC) analysis demonstrates that 
both (a) Arf–/– BCR-ABLWT and (b) Arf–/– BCR-ABLT315I LIC-based assays have 
high discriminatory power (AUC 0.83 and 0.85, respectively). 
 
The ROC curve is plotted as a function of % activity, and is color coded according to the 
right Y-axis. The ROC curves in gray are calculated from 200 bootstrap simulations. The 
dashed line corresponds to a random assay. 
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Figure 4.12. Frequency of ATC Level 1 (top) and ATC Level 2 (bottom) 
compounds for the 706 compounds submitted to secondary analysis.  
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Figure 4.13. High-throughput drug screen to identify novel agents possessing 
activity against IL7-mediated early (primary) and BCR-ABLMUTANT-mediated late 
(secondary) BCR-ABL–KI drug-resistant phenotypes. 
 
Clustering of validated hits using ATC therapeutic classification established by World 
Health Organization (WHO) (http://www.whocc.no/atc/structure_and_principles/). A 
single compound can be represented more than once because of multiple therapeutic 
indications, as is the case for the corticosteroids (highly active clusters in A, C, D, H, R, 
and S). This demonstrates that the active compounds come from drugs used to treat many 
indications. For details on clustering methodology, please refer to Chapter 3, and for 
details on clustering analysis, please refer to supplemental data in Appendix and Figure 
4.12. 
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 A correlative statistical analysis of NCI60 screening databases was performed. 
While a few validated hits demonstrated a significant positive (+) correlation between 
their anti-cancer activity and c-MYC expression across 60 human cancer cell lines, the 
phenotypic sensitivity to dasatinib was found not to be correlated (R = –0.11, where R is 
Pearsons coefficient of correlation) with c-MYC expression (Table 4.1). From the pool 
of validated hits demonstrating positive correlation with cellular c-MYC expression for 
their drug activity, we selected the artemisinin class of FDA-approved and very 
well-tolerated antimalarial drugs (ARTs) which included artemisinin, artesunate, and 
dihydroartemisinin (DHA) [104]. As a class, the ARTs were equipotent against Arf–/– 
BCR-ABLWT and Arf–/– BCR-ABLT315I LICs (Figure 4.14a) but the anti-LIC potency of 
artemisinin was much lower than that of artesunate or DHA. DHA and artesunate were 
also active against the human Ph+ ALL cell line SUP-B15 (Figure 4.14b) and had 
similar anti-Ph+ ALL potency in the presence of cell-extrinsic IL7 and cell-intrinsic 
over-expression of c-MYC, in stark contrast to dasatinib (Figure 4.14c). Studies have 
shown that DHA kills other genotypes of leukemic cells while selectively sparing normal 
human lymphocytes [105-106]. DHA, an active metabolite of many ARTs family 
members including artesunate, was chosen for further analysis because of its positive 
correlation for activity against tumor cells with relatively higher MYC expression 
(R = +0.5996, p = 0.0000433), in vitro potency, cellular selectivity, favorable 
pharmacokinetics, known bioavailability in hematopoietic system, and tolerability in all 
age groups. 
 
 
Dihydroartemisinin Possesses Single-agent In Vivo Activity against Ph+ ALL 
Phenotypes Demonstrating Primary and Acquired Dasatinib Resistance 
 
 DHA monotherapy gave significant dose-dependent survival benefit in IL7-WT 
host-mice bearing low-burden Arf–/– BCR-ABLWT LICs (Figure 4.15a). Leukemic 
samples collected from the relapsing mice at the time of sacrifice revealed the complete 
absence of ABL KD mutations, which are often selected with dasatinib treatment in this 
model. DHA monotherapy also gave a similar response against low-burden Arf–/– BCR-
ABLT315I leukemia, a disease that is completely refractory to dasatinib (Figure 4.15b). 
Thus, DHA is active in vivo against murine Ph+ ALL through a mechanism independent 
of the BCR-ABL kinase. 
 
 
Cotreatment with Dihydroartemisinin Overcomes Host-mediated Primary Drug-
resistance against Dasatinib and Eliminates Ph+ ALL In Vivo 
 
 Given that Arf–/– BCR-ABLWT leukemias in IL7-deficient mice were more 
sensitive to dasatinib (Figure 4.2e), and that DHA circumvented IL7 protection in vitro 
(Figure 4.14a and b) and displayed anti-Ph+ ALL activity in IL7-WT host mice (Figure 
4.15a and b), the potential for synergy between the two drugs was evaluated. This 
evaluation was performed in cohorts of IL7+/+ immuno-competent mice bearing high 
burdens of Arf–/– BCR-ABLWT Luc+ LIC-driven leukemia (analogous to IL7+/+ [WT]
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Table 4.1. Priortization of validated hits according to known human tolerability 
and predicted involvement of c-MYC expression in their anti-cancer drug action. 
 
Hits Active against Dasatinib Resistant 
Ph+ ALL Phenotypes* 
NSC No. for Hits 
in DTP Database 
R (Coefficient of 
Correlation)** 
GAMBOGIC ACID 693702 +0.59 
ARTESUNTE 712571 +0.59 
PATULIN 8120 +0.59 
DIHYDRO-ARTEMISINYL ETHER 685989 +0.57 
DIHYDRO-ARTEMISINYL ETHER 685988 +0.56 
ARTEMISININE 369397 +0.48 
MYCOPHENOLIC ACID 129185 +0.44 
CELASTROL 70931 +0.42 
THIRAM 1771 +0.40 
AKLAVINE HYDROCHLORIDE 100290 +0.40 
CHELERYTHRINE 36405 +0.36 
METHOTREXATE 740 +0.35 
EMETINE DIHYDROCHLORIDE  33669 +0.25 
ANTIMYCIN A 186 +0.06 
MITOXANTHRONE 
HYDROCHLORIDE 301739 +0.04 
MITOMYCIN C 26980 +0.04 
DASATINIB 732517 –0.11 
 
*   Examplary screening hits are presented for which preclinical and clinical toxicity data 
is available. 
 
** R was calculated between drug activity and c-MYC expression across NCI60 human 
cancer cell lines, using NSC numbers as chemical identifiers for identified hits. Total 
sample size of 4461 (4444 + 17) chemicals and drugs was used to calculate p values; 
see Chapter 3 for details. 
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Figure 4.14. Dihydroartemisinin of Artemisinin family of antimalarials 
circumvents dasatinib resistance induced by IL7, c-MYC overexpression and T315I 
mutation in vitro. 
 
(a) Arf–/– BCR-ABLWT (triangles) and Arf–/– BCR-ABLT315I (circles) LICs were treated 
with artemisinin, artesunate, dihydroartemisinin, or DMSO for 72 h in the absence (blue) 
or presence (red) of 1 ng/mL murine IL7, in triplicates. For each drug concentration, LIC 
growth (measured by the CTG-assay) was normalized to DMSO-treated LICs and fit 
using nonlinear regression (+/– sd). (b) Human Ph+ ALL SUP-B15 cells were treated 
with artesunate, dihydroartemisinin, or DMSO (no drug) for 72 h in the absence (blue) or 
presence (red) of 25 ng/mL human IL7. Viability was measured by the MTS assay. 
Values were normalized to DMSO-treated cells. (c) Heads-up comparison of potencies of 
dihydroartemisin and dasatinib against (i) Arf–/– BCR-ABLWT LICs +/– IL7, (ii) Arf–/– 
BCR-ABLWT LICs +/– c-MYC overexpression +/– IL7, and (iii) Arf–/– BCR-ABLWT 
LICs, using CTG-assay. 
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Figure 4.15. Dihydroartemisinin is active as a single agent against dasatinib-
resistant Ph+ ALL in IL7+/+ host mice. 
 
Kaplan-Meier survival curves showing the overall survival in response to therapy 
(survival benefit) in IL7+/+ Bl6 host mice that received day 0 tail vein injection of  
(a) 2 × 103 Arf–/– BCR-ABLWT Luc+ LICs; on day 3, once daily for 5 days of each week, 
vehicle, 100 mg/kg DHA, 200 mg/kg DHA, 300 mg/kg DHA, or 300 mg/kg DHA (for 3 
weeks only) therapy was initiated in mice bearing low burdens of BCR-ABLWT-driven 
leukemia, or (b) 2 × 103 Arf–/– BCR-ABLT315I Luc+ LICs; on day 3, once daily for 5 days 
of each week, vehicle, 300 mg/kg DHA, or 10 mg/kg dasatinib was given to mice bearing 
low burdens of BCR-ABLT315I-driven leukemia. 
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human patients carrying high burdens of Arf-deficient p185BCR-ABL pre-B cell leukemia at 
the time of diagnosis). Separate cohorts of animals were treated with dasatinib (10 
mg/kg), DHA alone (200 or 300 mg/kg) or binary combinations of dasatinib and DHA as 
shown in Figure 4.16a. Despite continuous monotherapy, dasatinib induced weak, 
transient primary responses. As a result, all animals harbored dasatinib-refractory 
persistent leukemia that inevitably led to relapse (Figure 4.16b) and caused death of all 
recipients within 6 weeks of initiating therapy (Figure 4.16a). DHA alone was 
completely ineffective (200 mg/kg) or weakly effective (300 mg/kg) in the high-burden 
leukemia model (Figure 4.16a). The combination of DHA and dasatinib significantly 
increased overall survival (Figure 4.16a), induced more rapid and deeper initial 
responses to dasatinib, and sensitized host-protected persistent leukemia to dasatinib 
(Figure 4.16b), in comparison to the treatment with either of the two drugs alone. Of the 
12 mice given 200 mg/kg DHA and 10 mg/kg dasatinib, 3 survived long term, apparently 
free of all leukemia despite cessation of therapy. All mice (n=12) given 300 mg/kg DHA 
and 10 mg/kg dasatinib survived the treatment period. After 4 weeks from the termination 
of combined therapy, 1 mouse succumbed to an isolated CNS relapse, which may be 
related to poor CNS penetration of dasatinib.[70-71]. Remarkably, the 14 surviving mice 
taken off the dasatinib and DHA combination regimens (3/12 at 200 mg/kg and 11/12 at 
300 mg/kg DHA) for one year show no trace of leukemia. This data strongly suggested 
that drug combination cured the disease because in this leukemia model all recipient 
animals left untreated invariably succumb to fatal, full-blown leukemia within 4 weeks of 
injecting a very low numbers of LICs, as shown in Figure 4.1. Dasatinib-DHA regimens 
were well tolerated in leukemic and non-leukemic mice, in congruence with prior work 
utilizing similar dosages of DHA [93] and other ART family members [107-108] in 
rodents [93, 107] and sheep [108]. 
 
 To extend our mechanistic understanding on DHA drug action, we identified 
genes whose expression levels were positively correlated with drug-sensitivity to DHA 
across 60 different human cancer cell lines, using public databases. We determined that 
the top 40 genes, which represent the drug-sensitivity signature for DHA in diverse 
human tumors, have a high and comparable expression in murine LICs and primary 
human Ph+ ALL leukemic samples with a positive correlation of 0.592 (p < 0.001) as 
shown in Figure 4.17. This data predicts that DHA may maintain its anti-leukemic drug 
action against primary Ph+ ALL in human patients, similar to its efficacious results in our 
genetically relevant murine leukemia model (Figure 4.16a). 
 
Next, to identify candidate genes targeted by DHA that plausibly resulted in 
overcoming host-cytokine mediated refractoriness against dasatinib, we compared gene 
signatures of DHA drug sensitivity (represented in Figure 4.17) and IL7-mediated 
dasatinib resistance (represented in Figure 4.6b). Three genes were found to overlap, 
namely MYC (probeset 1424942_a_at), Cabc1 (probeset 1417066_at, chaperone, ABC1 
activity of bc1 complex like (S. pombe)) and Akap1 (probeset 1449019_at, A kinase 
(PRKA) anchor protein 1) using a 2-fold change as a cut-off in the IL7-resistance 
signature, whereas setting a 4-fold cut-off left MYC as the only overlapping gene 
between the two sigantures. This provided an alternative confirmation for our results. 
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Figure 4.16. Dihydroartemisinin works synergistically with dasatinib to cure Ph+ 
ALL by improving primary responses to dasatinib. 
 
(a) Kaplan-Meier survival curves showing the survival benefit in response to therapy in 
IL7+/+ Bl6 host mice that received day 0 tail vein injection of 2×105 Arf–/– BCR-ABLWT 
Luc+ LICs. On day 7, six mouse groups bearing high burdens of BCR-ABLWT-driven 
leukemia were started on daily treatment for 5 days of each week, using two-dose 
regimens – 2 vehicles or 1 vehicle and 1 agent or 2 agents (see label), with 2 doses of 
each regimen given separately, 8 h apart, by oral gavage. On day 52, all therapy was 
terminated. (b) For 6 mouse groups in (a), separate graphs represent quantitative 
assessment of serial whole-animal luminescent signals (p/s/cm2/sr) acquired weekly. 
Solid lines represent imaging intensity of signal (y-axis) as a measure of leukemia burden 
from individual mice in the group, which is traced in real time on the x-axis. On day 7, 
before initiating therapy, all 6 groups had comparable and high burden of leukemia. The 
horizontal dotted line represents the empirically determined lower limit of sensitivity for 
luminescent signal as an experimental cut-off for detectable levels of persistent leukemia. 
Rectangular gray box quantifies experimental primary therapeutic response to indicated 
regimens; box-width depicts approximate time (days) to induce maximal initial response 
and box-depth represents maximal decrease achieved in leukemia burden signal. 
Increasing depth and decreasing width indicate stronger and quicker primary responses, 
respectively. 
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Figure 4.17. Statistical analyses to predict the activity of dihydroartemisin against 
human Ph+ ALL. 
 
‘Global anti-tumor activity signature’ i.e. top 40 genes positively correlated with 
sensitivity to DHA across 60 human cancer cell lines, of dihydroartemisinin was 
statistically determined (y-axis) and then its normalized cellular expression (x-axis) was 
compared in LICs (mouse, black) and primary Ph+ ALL samples collected at the time of 
diagnosis (human, white). Calculated R = +0.592 where R is the Pearson’s coefficient of 
correlation and p<0.001. 
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CHAPTER 5.    DISCUSSION AND CONCLUSIONS 
 
 
 The findings of this study reinforce a key therapeutic paradigm that in vivo 
responsiveness to host-derived growth factors may shield autonomous cancer cells from 
chemotherapy-induced cell killing. Host-derived signaling likely contributes to the 
frustratingly poor clinical performances of some targeting agents with potent in vitro 
activities. We designed a multi-modality platform that interrogates host-tumor-drug 
interactions in an unbiased manner. In this forward-building HT method, a logical battery 
of cell-based screens performed across collections of host-factors, short hairpin 
(sh)-RNAs and chemical libraries accelerates the identification of host-factor(s) and 
associated cell-intrinsic molecular change(s) that can impart drug-resistant phenotype(s) 
and leverages it for the development of improved therapeutic strategies. Applying this 
HT method to Ph+ ALL, we identified i) IL7 as the dominant cytokine from the tumor-
microenvironment that confers remarkable resistance to all FDA-approved BCR-ABL-
inhibitors, and ii) that anti-malarial drug DHA can reverse such host-IL7 mediated 
protection against dasatinib in vivo. This opens a novel potential avenue for clinical 
evaluation to treat human Ph+ ALL patients. 
 
 IL7 is essential for human T cell and post-fetal B cell development [109-110] and 
has a major contribution in the regulation and maintenance of mature T cells [111]. IL7 is 
constitutively produced by stromal cells in bone marrow, spleen, lymph nodes and 
thymus, among other tissues [112]. We propose a model in which IL7-rich niches harbor 
early persistent drug-refractory leukemias in humans [42, 44, 67, 113] and mice [63], 
with the presence of host-derived IL7 as the key driving factor behind the location of 
sequestration and the acquisition of resistance. 
 
 Results from cytokine-screens (Figure 4.2a) suggested that dasatinib resistance 
may be a more commonly prevalent host-dependent phenomenon, with IL7 [48, 114-115] 
as a predominant contributor in Ph+ ALL and other host-cytokines like TSLP [95], IL3 
[62, 69, 94], and IL4 playing a minor role. We show that although murine Arf–/–
BCR-ABLWT LICs bearing, analogous to human Ph+ ALL at diagnosis, are irreversibly 
committed to cell death on treatment with dasatinib alone [56], cell-extrinsic IL7 
reversibly sustains Ph+ ALL, despite therapy that effectively inhibits BCR-ABL in vivo 
[55] by at least temporarily over-riding their dependence on BCR-ABL kinase for 
sustenance (Figure 4.4) [37, 67-68]. Our demonstration of poor dasatinib responsiveness 
against BCR-ABLWT Ph+ ALL in IL7+/+ versus IL7–/– host-mice (Figure 4.2e) supports a 
novel role for physiological IL7 in drug resistance in vivo. The primary protection by 
host-IL7, coupled with higher leukemia burden in Ph+ ALL compared to CML in the 
clinical settings, likely directly contributes to the greater BCR-ABL–KI refractoriness in 
Ph+ ALL relative to CML. 
 
 Leukemogenesis by BCR-ABL oncoprotein is a complex process, and depends on 
constitutive expression of STAT5 [59] and c-MYC [60-62] for initial transformation and 
sustenance of Ph+ ALL. BCR-ABL either directly or indirectly through JAK2 drives the 
phosphorylation of STAT5 (pSTAT5) in the cytoplasm. Activated STAT5 (pSTAT5) 
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translocates to the nucleus and directly upregulates the expression of c-MYC [102]. This 
was confirmed by our failure to transform cellular bone marrow of STAT5-null mice 
with p185 isoform of BCR-ABL (data not shown). As demonstrated by others in human 
Ph+ cells [56, 62, 116], brief BCR-ABL inhibition in BCR-ABLWT LICs by dasatinib (no 
IL7) significantly decreased the levels of both pSTAT5 protein and expression of MYC 
and MYC target genes, committing leukemia blasts to death. The specificity of IL7 to 
attenuate the potency of only BCR-ABL inhibitors in both murine and human Ph+ ALL 
cells but not of those agents which inhibit targets other than BCR-ABL suggested that 
IL7 likely rescues a particular signaling pathway downstream of BCR-ABL to impart 
primary drug resistance. Further mechanistic studies revealed a model in which dasatinib 
blocks the essential BCR-ABL-JAK2-pSTAT5-c-MYC signaling but presence of 
cell-extrinsic IL7 rescues the critical expression of c-MYC and its target genes by 
phosphorylating STAT5 through parallel IL7-JAK3-pSTAT5-cMYC signaling, in a 
BCR-ABL-independent fashion [102]. The primary IL7-protection against dasatinib is 
relatively lower than the molecular drug resistance conferred by T315I mutation (Figure 
4.2b). Dasatinib does not inhibit BCR-ABL kinase or decreease the cellular level of 
pSTAT5 or c-MYC in BCR-ABLT315I human cells [117]. Interestingly, STAT activity 
[117-120] and expression of c-MYC [121] has recently been used as an explanation for 
resistance to imatinib. c-MYC has also been implicated by others in stroma-mediated 
drug resistance [66, 122]. Reinforcing our primary drug resistance model (Figure 4.7d), 
we show that overexpression of c-MYC imparts >100 fold resistance against dasatinib in 
the absence of both leukemia-extrinsic IL7 and leukemia-intrinsic ABL KD mutations. 
We propose c-MYC as a cellular node for primary drug resistance against BCR-ABL 
targeted therapy in Ph+ ALL.  
 
 A recent mechanistic study demonstrated direct de-repression of c-MYC by 
IKAROS haploinsufficiency in pre-B cells [103]. Our preliminary experiments depict that 
modeling the functional loss of IKAROS in BCR-ABLWT pre-B LICs by expression of 
DN IKAROS mutant, which increases c-MYC expression, imparts cell-intrinsic 
refractoriness against dasatinib and imatinib. IKAROS haploinsufficiency is a poor human 
prognostic marker [123] and is detected in leukemia samples obtained (at the time of 
diagnosis) from a large percentage of Ph+ ALL patients [75, 123] but almost never in 
chronic phase CML patients [75, 124]. Thus, IKAROS haploinsufficiency may also play a 
role in relative primary BCR-ABL–KI-resistance in Ph+ ALL, similar and in addition to 
that by host-IL7, which is a non-redundant cytokine present in all human patients. 
 
 In summary, repeated BCR-ABL–KI exposures in host-IL7 rich niches result in 
‘darwinian’ enrichment of leukemic blasts with relatively higher levels of pSTAT5 and 
c-MYC, and/or genetic mutations in IKAROS and Arf loci, accelerating the progression of 
disease. Selective multi-clonal clonal expansions follow [72, 125], leading to variance in 
therapeutic responses among human patients, similarly, BCR-ABL-mutations also 
accumulate with continuous therapy [50-51]. Acquisition of these complex changes 
impart niche-independent cell-intrinsic drug-resistance and clinically manifest as frank 
leukemic relapses [72, 125]. In lieu of our findings, high pSTAT5 protein and c-MYC 
expression level and loss of IKAROS in Ph+ lymphoblasts, and elevated levels of host 
IL7 can potentially be used as surrogates of primary BCR-ABL–KI drug resistance, 
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pending further preclinical and clinical confirmation. These markers may facilitate 
personalized medicine in future. 
 
 In keeping with critical homeostatic role of IL7 in immune-reconstitution [111], 
IL7 levels dramatically vary, inverse to individual patient’s absolute lymphocyte counts 
[126-127]. Current management of Ph+ ALL patients with BCR-ABL–KI-combined 
protocols deploy maximum tolerated dose (MTD)-guided conventional chemotherapy 
agents, high-dose corticosteroids, allo-HSCT and immune-suppressants, all of which 
induce profound iatrogenic-lymphopenias [126-127], and activate the immune IL7-axis 
[126-127] which can decrease the efficacy of BCR-ABL targeted therapy. Dasatinib 
therapy induces robust survival-benefit in human Ph+ ALL patients with prolonged 
lymphocytosis, which may arise from their inherent low levels of IL7, and vice versa 
[128]. Also, human Ph+ ALL patients with increased levels of pSTAT5, whose 
phosphorylation is triggered by IL7, respond poorly to imatinib therapy [129]. 
Collectively, these data strongly support the proposition that host-IL7 protection 
phenomenon contributes to BCR-ABL–KI-resistance in human patients. This suggests 
strategic amendments to current leukemia management to avoid prolonged lymphopenias. 
 
 From therapeutic perspective, BCR-ABL focused drug discovery aims at 
achieving more potent BCR-ABL inhibition, and views the escaped kinase activity due to 
ABL KD mutations, especially T315I, as an integral part of the problem [17-18]. In 
contrast, our host-tumor-drug interaction studies underscore the necessity for 
‘complementing’ pharmacological BCR-ABL-inhibition with strategies/drugs that 
circumvent primary host-cytokine protection and its associated cellular changes (pSTAT5 
levels and c-MYC expression) to accomplish long-lasting responses in Ph+ ALL. A 
clinically-validated strategy to overcome drug resistance is to concomitantly use multiple 
agents whose mechanism of action, and therefore of drug resistance, vary significantly, as 
illustrated by the success of the combination chemotherapy regimens against various 
cancers and the highly active anti-retroviral therapy (HAART) against HIV [130]. 
Likewise, we adapted drug resistant phenotypes, mediated by host-IL7 and BCR-ABL 
T315I mutation, into our flexible cell-based platform and deployed a HT screen across a 
library of 3200 known drugs and natural products to select active agents, ideal for 
combined use with BCR-ABL–KIs in vivo. 
 
 Our approach accurately confirmed activities of various chemotherapeutic agents 
and majority of clinically used anti-leukemic drugs, many of which enhance the clinical 
and preclinical performances of BCR-ABL–KIs [44-45, 63]. In addition, several novel 
chemotypes were identified to be active against primary host-IL7 and late BCR-ABL 
mutation mediated drug-resistant phenotypes of Ph+ ALL. These chemically-diverse hits 
are non-BCR-ABL specific and inhibit cellular targets ‘downstream’ of BCR-ABL or 
outside its ATP-binding or allosteric site. By definition, such agents cannot be identified 
by biochemical kinase binding assays or target-drug structural modeling, which form the 
backbone of target-focused approach. Our results predict that an ideal BCR-ABL–KI 
should additionally inhibit JAK1/JAK3 kinase activity to prevent relay of drug-refractory 
signal from the activated IL7 surface receptor to the inside of leukemic lymphoblast. A 
review of public kinase-binding profiles of imatinib and dasatinib [20] confirms their 
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inability to inhibit JAK1/JAK3 kinase activity. Until BCR-ABL–KIs with additional 
JAK3-inhibiting activity become available, empirically determined drug combinations of 
BCR-ABL–KIs are bound to play an important bridging role in Ph+ ALL therapeutics. 
 
 In support of our phenotypic complementation strategy, we characterized the 
anti-leukemia activities of one screening hit, the orally-bioavailable, well-tolerated 
antimalarial drug DHA [104], in detail. The biggest challenges in curing Ph+ ALL using 
BCR-ABL–KIs are poor primary responses, persistence of disease, invariant relapses, 
and late BCR-ABL mutational resistance. DHA, acting mechanistically independent of 
BCR-ABL–KIs (Figures 4.14 and 4.15), synergistically corrects the deficiencies 
associated with dasatinib monotherapy (Figure 4.16b), and achieves near-complete 
long-term survival in a robust murine model of human Ph+ ALL. Distinct from its 
anti-malarial drug action [131-132], drug sensitivity to the ARTs family across various 
cancer types appears to correlate with relative c-MYC expression. While it has been 
shown that DHA induces apoptosis in cancer cells by selectively accelerating the 
degradation of c-MYC [133], our preliminary bio-physical studies (Singh and Kriwacki, 
unpublished), using previously validated assays, indicate that DHA directly binds to 
basic-helix-loop-helix domain of c-MYC. Most importantly, as described earlier (Figures 
4.6 and 4.7), c-MYC is the converging node of primary dasatinib resistance, and targeting 
c-MYC, using dominant negative approaches, has been validated as a 
BCR-ABL-independent therapeutic intervention in pre-B Ph+ ALL [60-61]. Thus, DHA 
might augment BCR-ABL–KI therapy by accelerating the degradation of c-MYC, 
thereby countering the protective effects of IL7. 
 
 The accelerated characterization of anti-malarial drug DHA for a new 
anti-leukemic use was linked to our original decision of testing only a small but focused 
collection of very well-characterized bioactive agents and drugs, and their mechanistic 
evaluation in DTP screening drug databases [89, 134-135]. In past, this strategy has made 
immense and rapid contributions in the field of mechanistic drug discovery [90-91, 134, 
136-137]. In addition to ARTs family, anti-tumor activity of gambogic acid and 
mycophenolic acid was also found to be statistically correlated with high MYC 
expression in NCI60 human cancer cell lines (Table 4.1), and could be considered to 
target dasatinib-resistant Ph+ ALL. However, direct involvement of c-MYC in the 
mechanism of action of these two alternative agents remains to be experimentally proven 
[138-140]. Further, Gambogic acid, a natural resin product, has never been tested in 
humans, and mycophenolic acid is an FDA-approved agent but induces 
immunosuppression and lymphopenia [138, 141]. In contrast, DHA selectively kills 
leukemic cells while sparing normal lymphocytes [105-106], therefore is less likely to 
induce host-IL7. We determined that gene signature predicting sensitivity to DHA across 
human tumors of 9 different tissue lineages (Figure 4.17) is expressed with a high degree 
of similarity in murine LICs and primary samples obtained from human Ph+ ALL 
patients. It is noteworthy that DHA-dasatinib combination is significantly more 
efficacious than our previous experience with triple combination between dasatinib, 
dexamethasone and asparaginase [63]. Collectively, these data strongly support the 
testing of efficacy of BCR-ABL–KI/DHA co-therapy for the clinical management of 
human patients with high-risk Ph+ ALL. 
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 Complementing BCR-ABL and alternative target-focused drug pipelines [15-16, 
19-20, 23] with our host-tumor-drug screening approach can timely predict mechanisms 
and biomarkers of clinical drug-resistance. A holistic approach encompassing these 
features can improve the prioritization of hits and facilitate improvement in design of 
agents against Ph+ ALL and other cancers in future [15-16, 19-20, 23]. Broader 
implementation of reported screening model will also address two important and 
inter-related issues which remain pending. First, whether the overly-specific targeting 
nature of the modern era oncology drugs, relative to the non-specific drugs, renders them 
more vulnerable to compensatory (cell extrinsic/intrinsic) parallel pathways in the tumor 
cells, and second, what is the extent of this problem among the current clinically 
approved agents. 
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APPENDIX. SUPPLEMENTAL DATA 
 
 
 Supplemental data is made available online in the form of a Microsoft Excel file 
which contains eight (i through viii) separate worksheets – i) table of contents (comprised 
of description, legends and experimental notes for the subsequent worksheets ii through 
viii which contain real experimental data), ii) host factors, iii) gene expression 1, iv) gene 
expression 2, v) structure, vi) drug screen summary 1, vii) drug screen summary 2, and 
viii) ATC classification. The Excel file is approximately 3.8Mbytes and can be 
downloaded from http://etd.uthsc.edu/World-Access/Singh/Supplementaldata.xlsx. 
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